[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 203
1. Pérez-Campos-Mayoral L, Ruiz-Argüelles A, Pérez-Romano B, Zenteno E, Hernández-Cruz P, Martínez-Cruz R, Martínez-Cruz M, Pina-Canseco S, Pérez-Campos E: Potential use of the Macrobrachium rosenbergii lectin for diagnosis of T-cell acute lymphoblastic leukemia. Tohoku J Exp Med; 2008 Jan;214(1):11-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential use of the Macrobrachium rosenbergii lectin for diagnosis of T-cell acute lymphoblastic leukemia.
  • T-cell acute lymphoblastic leukemia is the most common form of cancer in children.
  • Lectins are proteins or glycoproteins from plants or animals that recognize oligossacharides on the cell surface and have been used to characterize the structural changes of oligosaccharides in leukemias.
  • In this study, we used the lectin from the freshwater prawn Macrobrachium (M. rosenbergii), specific for acetyl groups in sialylated glycans, because increased sialylation of glycoproteins and glycolipids has been identified in lymphoblastic leukemias.
  • We compared the specificity of the M. rosenbergii lectin for lymphoblastic leukemias with the specificities of the lectins from Triticum vulgaris, Solanum tuberosum, Arachis hipogaea, and Phytolacca americana.
  • By morphologic and phenotype characterization with a panel of monoclonal antibodies, we identified four types of leukemias from 106 leukemia patients: 11 cases of T-cell acute lymphoblastic leukemia, 61 cases of B-cell acute lymphoblastic leukemia, 24 cases of acute myeloblastic leukemia, and 10 cases of acute biphenotypic leukemia.
  • As determined by cytofluorometric assays, nine of the eleven cases with T-cell acute lymphoblastic leukemia (8 +/- 3 years old) were specifically identified with the lectin from M. rosenbergii.
  • In contrast, only six cases of B-cell leukemia, one case of myeloblastic leukemia, and 2 cases of biphenotypic leukemia were identified with this M. rosenbergii lectin.
  • The other lectins tested showed no capacity to differentiate, in a significant manner, any of the four types of leukemias tested.
  • Thus, the lectin from M. rosenbergii could be considered a useful tool for the diagnosis and study of T-cell acute lymphoblastic leukemia.
  • [MeSH-major] Lectins. Leukemia, Biphenotypic, Acute / diagnosis. Palaemonidae / chemistry
  • [MeSH-minor] Animals. Antibodies, Monoclonal. Antigens, CD45 / analysis. Antigens, Neoplasm / immunology. Child. Diagnosis, Differential. Flow Cytometry. Humans. Lymphocytes / drug effects. Lymphocytes / metabolism. Phenotype

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212483.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Lectins; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


2. Lightfoot T: Aetiology of childhood leukemia. Bioelectromagnetics; 2005;Suppl 7:S5-S11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aetiology of childhood leukemia.
  • Leukemia is the most common cancer to affect children, accounting for approximately a third of all childhood cancers.
  • The major morphological subtypes of leukemia, acute lymphoblastic leukemia (ALL), and acute myeloblastic leukemia (AML), are characterized by chromosomal translocations involving over 200 genes including mixed lineage leukemia (MLL), TEL, and AML1.
  • Chromosomal translocations involving the MLL gene at 11q23 are a common feature of infant acute leukemia, found in up to 80% of all cases, and there is strong evidence that rearrangements involving the MLL gene or the TEL-AML1 gene fusion can originate in utero.
  • As with most other cancers, the mechanism by which leukemia arises is likely to involve gene-environment interactions.
  • Accordingly, it is important to identify exposures that cause DNA damage and induce chromosome breaks which are inadequately repaired, ultimately leading to the initiation and disease progression.
  • Exposures acting before birth and early in life has long been thought to be important determinants of leukemia, and the list of suspected chemical, physical, and biological agents continues to increase.
  • Unfortunately, the evidence regarding the majority of suggested exposures is limited and often contradictory, and there are areas, which clearly warrant further investigation in order to further our understanding of the aetiology of childhood leukemia.
  • [MeSH-major] Electromagnetic Fields / adverse effects. Environmental Exposure / adverse effects. Leukemia, Radiation-Induced / etiology. Leukemia, Radiation-Induced / physiopathology. Prenatal Exposure Delayed Effects / etiology. Prenatal Exposure Delayed Effects / physiopathology

  • MedlinePlus Health Information. consumer health - Electromagnetic Fields.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 16059922.001).
  • [ISSN] 0197-8462
  • [Journal-full-title] Bioelectromagnetics
  • [ISO-abbreviation] Bioelectromagnetics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


3. Shen M, Yen A: Nicotinamide cooperates with retinoic acid and 1,25-dihydroxyvitamin D(3) to regulate cell differentiation and cell cycle arrest of human myeloblastic leukemia cells. Oncology; 2009;76(2):91-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nicotinamide cooperates with retinoic acid and 1,25-dihydroxyvitamin D(3) to regulate cell differentiation and cell cycle arrest of human myeloblastic leukemia cells.
  • Nicotinamide, the amide derivative of vitamin B(3), cooperates with retinoic acid (RA), a form of vitamin A, and 1,25-dihydroxyvitamin D(3) (D3), to regulate cell differentiation and proliferation of human myeloblastic leukemia cells.
  • In human myeloblastic leukemia cells, RA or D3 are known to cause MAPK signaling leading to myeloid or monocytic differentiation and G0 cell cycle arrest.
  • [MeSH-major] Calcitriol / metabolism. Leukemia, Myelomonocytic, Acute / drug therapy. Niacinamide / administration & dosage. Tretinoin / administration & dosage

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 1987 Jan;168(1):247-54 [3023118.001]
  • [Cites] Blood. 1983 Oct;62(4):709-21 [6192859.001]
  • [Cites] Diabetologia. 1989 May;32(5):316-21 [2526769.001]
  • [Cites] Science. 1990 Sep 21;249(4975):1429-31 [2402637.001]
  • [Cites] Science. 1993 Nov 12;262(5136):1056-9 [8235624.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Nov 15;196(3):1459-65 [8250903.001]
  • [Cites] Prog Clin Biol Res. 1995;392:369-73 [8524944.001]
  • [Cites] Blood. 1996 Jan 1;87(1):227-37 [8547646.001]
  • [Cites] Immunogenetics. 1996;45(1):35-43 [8881035.001]
  • [Cites] FEBS Lett. 1997 Aug 11;413(1):99-103 [9287124.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3163-72 [9679985.001]
  • [Cites] Biosci Biotechnol Biochem. 1998 Dec;62(12):2351-6 [9972261.001]
  • [Cites] Immunogenetics. 1999 Jul;49(7-8):597-604 [10369916.001]
  • [Cites] Mol Cell. 2005 Apr 1;18(1):83-96 [15808511.001]
  • [Cites] J Cell Physiol. 2005 Sep;204(3):964-74 [15799027.001]
  • [Cites] Horm Metab Res. 2006 Jan;38(1):12-5 [16477534.001]
  • [Cites] J Cell Biochem. 2006 Apr 15;97(6):1328-38 [16329108.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jul;7(7):517-28 [16829982.001]
  • [Cites] Autoimmunity. 2006 Jun;39(4):333-40 [16891222.001]
  • [Cites] Biochem Pharmacol. 2007 Mar 15;73(6):831-42 [17188249.001]
  • [Cites] Ann N Y Acad Sci. 2006 Dec;1091:356-67 [17341628.001]
  • [Cites] Mol Med. 2006 Nov-Dec;12(11-12):334-41 [17380201.001]
  • [Cites] Eur Respir J. 2007 Aug;30(2):199-204 [17504797.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8624-32 [17875702.001]
  • [Cites] J Biol Chem. 2008 Feb 15;283(7):4375-86 [18006504.001]
  • [Cites] Diabetologia. 2000 Nov;43(11):1337-45 [11126400.001]
  • [Cites] J Virol. 2001 Jun;75(11):5302-14 [11333911.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):13-22 [11689561.001]
  • [Cites] Exp Biol Med (Maywood). 2002 Oct;227(9):753-62 [12324654.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49453-8 [12386160.001]
  • [Cites] Clin Exp Immunol. 2003 Jan;131(1):48-52 [12519385.001]
  • [Cites] Curr Med Chem. 2003 Feb;10(4):321-40 [12570705.001]
  • [Cites] Biosci Biotechnol Biochem. 2003 May;67(5):1132-5 [12834294.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2146-55 [12763926.001]
  • [Cites] Transplant Proc. 2003 Aug;35(5):2021-3 [12962883.001]
  • [Cites] Proc Soc Exp Biol Med. 1969 Mar;130(3):992-4 [4304354.001]
  • [Cites] Leuk Res. 1987;11(2):191-6 [3469486.001]
  • (PMID = 19127080.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA033505
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD11b; 0 / Antigens, CD14; 25X51I8RD4 / Niacinamide; 5688UTC01R / Tretinoin; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.2.2.5 / Antigens, CD38; FXC9231JVH / Calcitriol
  • [Other-IDs] NLM/ PMC2826433
  •  go-up   go-down


Advertisement
4. Chan WK, Cheung CC, Law HK, Lau YL, Chan GC: Ganoderma lucidum polysaccharides can induce human monocytic leukemia cells into dendritic cells with immuno-stimulatory function. J Hematol Oncol; 2008;1:9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ganoderma lucidum polysaccharides can induce human monocytic leukemia cells into dendritic cells with immuno-stimulatory function.
  • The question of how leukemic cells especially in monocytic lineage respond to GL-PS stimuli remains unclear.
  • RESULTS: In this study, we used in vitro culture model with leukemic monocytic cell-lines THP-1 and U937 as monocytic effectors cells for proliferation responses and DCs induction.
  • CONCLUSION: Our findings suggested that GL-PS could induce selected monocytic leukemic cell differentiation into DCs with immuno-stimulatory function.
  • The possible clinical impact of using this commonly used medicinal mushroom in patients with monocytic leukemia (AML-M4 and M5) deserved further investigation.
  • [MeSH-major] Adjuvants, Immunologic / pharmacology. Dendritic Cells / immunology. Leukemia / immunology. Monocytes / immunology. Polysaccharides / immunology. Reishi / chemistry

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2000 Sep-Oct;22(5):412-6 [11037851.001]
  • [Cites] Leuk Res. 2006 Jul;30(7):841-8 [16423392.001]
  • [Cites] J Immunol. 2001 Nov 15;167(10):6021-30 [11698483.001]
  • [Cites] Blood. 2002 Jul 15;100(2):701-3 [12091369.001]
  • [Cites] Immunol Lett. 2002 Oct 1;83(3):163-9 [12095706.001]
  • [Cites] Pediatr Res. 2003 Jul;54(1):105-12 [12672905.001]
  • [Cites] J Altern Complement Med. 2003 Aug;9(4):491-7 [14499024.001]
  • [Cites] Oncol Rep. 2004 Sep;12(3):659-62 [15289852.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 8;323(1):133-41 [15351712.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1983 Spring;5(1):65-71 [6859456.001]
  • [Cites] Anticancer Res. 1992 Jul-Aug;12(4):1211-5 [1503411.001]
  • [Cites] Crit Rev Immunol. 1999;19(1):65-96 [9987601.001]
  • [Cites] Acta Pharmacol Sin. 2004 Nov;25(11):1387-95 [15525457.001]
  • [Cites] J Immunol. 2004 Nov 15;173(10):5989-99 [15528333.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 5;333(3):896-907 [15963458.001]
  • [Cites] J Leukoc Biol. 2005 Aug;78(2):533-43 [15894585.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):777-80 [16115136.001]
  • [Cites] J Altern Complement Med. 2005 Dec;11(6):1047-57 [16398597.001]
  • [Cites] Exp Mol Med. 2006 Feb 28;38(1):72-84 [16520555.001]
  • [Cites] J Altern Complement Med. 2001 Jun;7(3):281-7 [11439851.001]
  • (PMID = 18644156.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Polysaccharides; 130068-27-8 / Interleukin-10; 187348-17-0 / Interleukin-12; 207137-56-2 / Interleukin-4; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Other-IDs] NLM/ PMC2517069
  •  go-up   go-down


5. Cuiffo B, Ren R: Palmitoylation of oncogenic NRAS is essential for leukemogenesis. Blood; 2010 Apr 29;115(17):3598-605
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activating mutations of NRAS are common in acute myeloid leukemia, chronic myelomonocytic leukemia, and myelodysplastic syndrome.
  • We have previously shown that expression of oncogenic NRAS using a bone marrow transduction and transplantation model efficiently induces a chronic myelomonocytic leukemia- or acute myeloid leukemia-like disease in mice.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PALMITIC ACID .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30451-7 [10852915.001]
  • [Cites] Prog Lipid Res. 2009 May-Jul;48(3-4):117-27 [19233228.001]
  • [Cites] Oncogene. 2001 Jul 5;20(30):3949-58 [11494123.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8758-68 [11751396.001]
  • [Cites] Science. 1999 Nov 26;286(5445):1741-4 [10576742.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):6105-13 [10913192.001]
  • [Cites] Nat Cell Biol. 2002 May;4(5):343-50 [11988737.001]
  • [Cites] Cancer Treat Res. 2003;115:189-208 [12613198.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 May;4(5):373-84 [12728271.001]
  • [Cites] Nature. 2003 Aug 7;424(6949):694-8 [12845332.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(8):3485-96 [15060167.001]
  • [Cites] Oncogene. 2004 Apr 19;23(18):3138-44 [15094763.001]
  • [Cites] J Biol Chem. 2004 Sep 3;279(36):37398-406 [15210703.001]
  • [Cites] Nature. 1984 Aug 16-22;310(5978):583-6 [6087162.001]
  • [Cites] Science. 1987 Jul 31;237(4814):532-5 [2440107.001]
  • [Cites] Cell. 1989 Jun 30;57(7):1167-77 [2661017.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]
  • [Cites] Cell. 1990 Oct 5;63(1):133-9 [2208277.001]
  • [Cites] EMBO J. 1992 Feb;11(2):569-74 [1371463.001]
  • [Cites] EMBO J. 1992 Nov;11(11):3941-51 [1396587.001]
  • [Cites] J Biol Chem. 1995 Mar 17;270(11):6221-6 [7890759.001]
  • [Cites] J Biol Chem. 1997 Jun 20;272(25):15591-4 [9188444.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3829-40 [9808576.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):6918-28 [10490629.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1098-101 [15718470.001]
  • [Cites] Science. 2005 Mar 18;307(5716):1746-52 [15705808.001]
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):31141-8 [16000296.001]
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):31101-8 [16006564.001]
  • [Cites] J Biol Chem. 2005 Dec 9;280(49):40406-16 [16221682.001]
  • [Cites] Biochim Biophys Acta. 2005 Dec 30;1746(3):274-83 [16039730.001]
  • [Cites] Curr Opin Cell Biol. 2006 Apr;18(2):162-7 [16488589.001]
  • [Cites] J Lipid Res. 2006 May;47(5):883-91 [16543601.001]
  • [Cites] Nat Rev Genet. 2006 Aug;7(8):606-19 [16847462.001]
  • [Cites] Mol Cancer Ther. 2006 Jul;5(7):1647-59 [16891450.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2349-57 [16763213.001]
  • [Cites] Methods. 2006 Oct;40(2):177-82 [17012030.001]
  • [Cites] Blood. 2007 Jan 15;109(2):763-8 [16973961.001]
  • [Cites] Biophys J. 2007 Feb 1;92(3):808-15 [17098795.001]
  • [Cites] Blood Rev. 2007 Jul;21(4):173-82 [17293017.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1261-74 [17604717.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7139-46 [17671181.001]
  • [Cites] Nat Cell Biol. 2007 Aug;9(8):905-14 [17618274.001]
  • [Cites] Cell Mol Life Sci. 2007 Oct;64(19-20):2575-89 [17628742.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):133-40 [18219307.001]
  • [Cites] Cell Cycle. 2008 Jan 15;7(2):127-34 [18212529.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1357-65 [18502828.001]
  • [Cites] Mol Membr Biol. 2009 Jan;26(1):80-92 [19115142.001]
  • [Cites] J Cell Sci. 2001 May;114(Pt 9):1603-8 [11309191.001]
  • (PMID = 20200357.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL083515; United States / NHLBI NIH HHS / HL / R01HL083515
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 2V16EO95H1 / Palmitic Acid; EC 2.5.1.29 / Farnesyltranstransferase; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  • [Other-IDs] NLM/ PMC2867268
  •  go-up   go-down


6. Draper NL, Conley C, Smith C, Benson K: Dispermic chimerism identified during HLA typing for stem cell transplantation. Transfusion; 2008 Jul;48(7):1398-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: A 32-year-old man was diagnosed with acute myelomonocytic leukemia.
  • Molecular HLA typing may increase the accurate identification of phenotypically normal chimeras and aid in selecting proper donors for transplantation to reduce graft-versus-host disease and transplant rejection in these patients.
  • [MeSH-minor] Adult. HLA-B Antigens / genetics. HLA-C Antigens / genetics. Haplotypes / genetics. Humans. Leukemia, Myelomonocytic, Acute / surgery. Male. Microsatellite Repeats / genetics. Sequence Analysis, DNA

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18422842.001).
  • [ISSN] 0041-1132
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-B Antigens; 0 / HLA-C Antigens
  •  go-up   go-down


7. Mayayo E, Landeyro J, Stchigel AM, Gazzoni A, Capilla J: [Perineural spread by fungal cells. Case report and literature review]. Rev Iberoam Micol; 2010 Jun 30;27(2):94-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Infiltración perineural por células fúngicas. Presentación de un caso y revisión de la literatura.
  • We present a clinical case of a 73-year-old male, with diabetes and acute myelomonocytic leukaemia that began with tumefaction on the left side of his face, spreading to the sinus with invasion of the soft tissues and fistulae in the oral cavity.
  • Clinical examination showed cerebral involvement.
  • [MeSH-minor] Aged. Blast Crisis / complications. Diabetes Mellitus, Type 2 / complications. Disease Progression. Fatal Outcome. Humans. Immunocompromised Host. Leukemia, Myelomonocytic, Chronic / complications. Lung Diseases, Fungal / microbiology. Male

  • MedlinePlus Health Information. consumer health - Sinusitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Revista Iberoamericana de Micología. Published by Elsevier Espana. All rights reserved.
  • (PMID = 20347372.001).
  • [ISSN] 1130-1406
  • [Journal-full-title] Revista iberoamericana de micología
  • [ISO-abbreviation] Rev Iberoam Micol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 18
  •  go-up   go-down


8. Wang TY, Huang XO, Xu CG, Chen XC, Wang H: [Acute myelomonocytic leukemia occurred after multiple myeloma treated: a case report]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Mar;38(2):347-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute myelomonocytic leukemia occurred after multiple myeloma treated: a case report].
  • We reported a case of multiple myeloma, who suffered from the acute myelomonocytic leukemia (AML-M4) after the chemotherapy of alkylating agent.
  • Thus, the diagnosis of multiple myeloma in remission and secondary AML-M4 was established.
  • When the chemotherapy regimen to AML was being planned for this patient, she died of massive hemorrhage of gastrointestinal tract due to thrombocytopenia and ineffectiveness.
  • [MeSH-major] Leukemia, Myelomonocytic, Acute / diagnosis. Multiple Myeloma / drug therapy


9. Sakagami H, Kishino K, Kobayashi M, Hashimoto K, Iida S, Shimetani A, Nakamura Y, Takahashi K, Ikarashi T, Fukamachi H, Satoh K, Nakashima H, Shimizu T, Takeda K, Watanabe S, Nakamura W: Selective antibacterial and apoptosis-modulating activities of mastic. In Vivo; 2009 Mar-Apr;23(2):215-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among a total of thirteen human cell types, promyelocytic leukemia HL-60 was the most sensitive to the cytotoxicity of mastic, followed by myeloblastic leukemia (ML-1, KG-1), erythroleukemia (K-562), oral squamous cell carcinoma (HSC-2, HSC-3, HSC-4), hepatocellular carcinoma (HepG2), glioblastoma (T98G, U87MG) and normal oral cells (gingival fibroblast, pulp cell, periodontal ligament fibroblast, most resistant).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Putrescine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414406.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Resins, Plant; 61789-92-2 / gum mastic; EC 3.4.22.- / Caspase 3; V10TVZ52E4 / Putrescine
  •  go-up   go-down


10. Corazza F, Hermans C, D'Hondt S, Ferster A, Kentos A, Benoît Y, Sariban E: Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia. Blood; 2006 Mar 15;107(6):2525-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia.
  • We studied patients with acute lymphoblastic leukemia (ALL) or acute myeloblastic leukemia (AML) and used TPO-induced c-fos protein up-regulation as a marker of c-mpl functionality and observed that c-mpl-presenting blast cells were present in 62% (37 of 60) of patients with ALL but that c-mpl was nonfunctional in 0 of 28 patients and that they were present in 56% (22 of 39) of patients with AML and were functional in 43% (12 of 28).
  • Adequate increases in serum TPO level in response to thrombocytopenia were seen in patients with ALL and with c-mpl-deficient (c-mpl-) AML.
  • In contrast, in patients with c-mpl-proficient (c-mpl+) AML, TPO levels were found to be inappropriately low but increased to expected values during induction chemotherapy as blasts disappeared.
  • In vitro significant TPO-associated blast cell proliferation or decreased apoptosis was observed only in patients with c-mpl+ AML compared with ALL or c-mpl- AML and was highly correlated with low in vivo TPO levels (P < .001).
  • These data suggest that, in patients with AML, inadequate TPO levels are secondary to TPO clearing by functional c-mpl receptor myeloid blast cells and that TPO may serve as an in vivo myeloid leukemic growth factor in a significant number of patients.
  • [MeSH-major] Blast Crisis / pathology. Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Thrombopoietin / blood
  • [MeSH-minor] Acute Disease. Apoptosis. Cell Proliferation. Growth Substances / blood. Humans. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins / physiology. Receptors, Cytokine / analysis. Receptors, Cytokine / physiology. Receptors, Thrombopoietin. Thrombocytopenia / blood

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16317100.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Growth Substances; 0 / Proto-Oncogene Proteins; 0 / Receptors, Cytokine; 0 / Receptors, Thrombopoietin; 143641-95-6 / MPL protein, human; 9014-42-0 / Thrombopoietin
  •  go-up   go-down


11. Liu LB, Li WM, He W, Zhang M, Xiao J, Zhong ZD, Li L, Zou P: [Blocking the escape of leukemic cells from killing of T cell by combining anti-Fas ribozyme and CD80-IgG fusion protein]. Zhonghua Yi Xue Za Zhi; 2005 Dec 28;85(49):3469-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study Fas expression regulation of cytotoxic T lymphocyte(CTL)via anti-Fas ribozyme, increasing of CD80 epitope on the surface of acute myelomonocytic leukemia cells by CD80-IgG fusion protein and their effects on the apoptosis and killing ability against acute myelomonocytic leukemia cells of CTL.
  • Then allogeneic mixed lymphocytes culture between the mouse spleen T cells transfected with pEGFP-RZ596 and WEHI-3 cells (mouse acute myelomonocyte leukemia cell line) incubated with CD80-IgG fusion protein was performed.
  • [MeSH-minor] Animals. Antigens, CD80 / genetics. Antigens, CD80 / immunology. Antigens, CD80 / metabolism. Antigens, CD95 / genetics. Antigens, CD95 / immunology. Antigens, CD95 / metabolism. Blotting, Western. CHO Cells. Cell Line, Tumor. Coculture Techniques. Cricetinae. Cricetulus. Female. Green Fluorescent Proteins / genetics. Green Fluorescent Proteins / metabolism. Immunoglobulin G / genetics. Immunoglobulin G / immunology. Immunoglobulin G / metabolism. Leukemia, Myelomonocytic, Acute / immunology. Leukemia, Myelomonocytic, Acute / metabolism. Leukemia, Myelomonocytic, Acute / pathology. Mice. Mice, Inbred BALB C. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Tumor Escape

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686062.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Antigens, CD95; 0 / Immunoglobulin G; 0 / RNA, Catalytic; 0 / Recombinant Fusion Proteins; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


12. Freycon F, Trombert-Paviot B, Casagranda L, Bertrand Y, Plantaz D, Marec-Bérard P: Trends in treatment-related deaths (TRDs) in childhood cancer and leukemia over time: a follow-up of patients included in the childhood cancer registry of the Rhône-Alpes region in France (ARCERRA). Pediatr Blood Cancer; 2008 Jun;50(6):1213-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in treatment-related deaths (TRDs) in childhood cancer and leukemia over time: a follow-up of patients included in the childhood cancer registry of the Rhône-Alpes region in France (ARCERRA).
  • No difference was observed in treatment- and transplantation-related deaths in patients with acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML), but OS was better in patients with AML (P = 0.02).
  • Severe graft-versus-host disease was also observed among patients with ALL (P = 0.036).
  • CONCLUSION: Although mortality declined, improved adherence to therapeutic guidelines and more restricted indications of allograft are needed to preclude further treatment- and transplantation-related deaths, particularly among those with leukemia.
  • [MeSH-minor] Central Nervous System Neoplasms / mortality. Central Nervous System Neoplasms / therapy. Child. Cohort Studies. Female. France / epidemiology. Guideline Adherence. Hematopoietic Stem Cell Transplantation / mortality. Humans. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Male. Practice Guidelines as Topic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Registries

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18300318.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Numakura K, Tsuchiya N, Habuchi T, Takahashi N: [Therapy related leukemia with 11q23 abnormality induced by chemotherapy consisted of docetaxel for advanced prostatic carcinoma: case report]. Nihon Hinyokika Gakkai Zasshi; 2009 Jul;100(5):580-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy related leukemia with 11q23 abnormality induced by chemotherapy consisted of docetaxel for advanced prostatic carcinoma: case report].
  • A balanced translocation involving 11q23 (MLL gene) could be observed in therapy related leukemia (TRL) patients generally treated with topoisomerase II inhibitors.
  • Herein, we report a patient who developed acute myelomonocytic leukemia (AMMoL) with t (9;. 11) (p22;.
  • Although, no disease progression of the prostatic carcinoma was observed, AMMoL with t (9;. 11) (p22;.
  • q23) translocation and clinical course.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma / therapy. Chromosomes, Human, Pair 11 / genetics. Leukemia, Myelomonocytic, Acute / chemically induced. Leukemia, Myelomonocytic, Acute / genetics. Neoplasms, Second Primary. Prostatic Neoplasms / therapy. Taxoids / adverse effects. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19663246.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel
  • [Number-of-references] 23
  •  go-up   go-down


14. Fujisawa S, Naito K, Matsuoka T, Kobayashi M: Complete remission induced by gemtuzumab ozogamicin in a Jehovah's Witness patient with acute myelogenous leukemia. Int J Hematol; 2007 Jun;85(5):418-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission induced by gemtuzumab ozogamicin in a Jehovah's Witness patient with acute myelogenous leukemia.
  • We report an interesting case of acute myelogenous leukemia (AML) in a Jehovah's Witness patient.
  • The patient's diagnosis was AML (M4).
  • [MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Jehovah's Witnesses. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2000 Dec;111(4):1103-5 [11167746.001]
  • [Cites] Am J Hematol. 1996 Mar;51(3):251-2 [8619417.001]
  • [Cites] Br J Haematol. 1998 Mar;100(4):664-8 [9531331.001]
  • [Cites] Leukemia. 2005 Feb;19(2):176-82 [15592433.001]
  • [Cites] J Intern Med. 2000 May;247(5):521-34 [10809991.001]
  • [Cites] Cancer. 2003 Nov 15;98 (10 ):2095-104 [14601078.001]
  • [Cites] Ann Hematol. 1998 Jan;76(1):43-4 [9486924.001]
  • [Cites] Leuk Lymphoma. 2005 Aug;46(8):1115-20 [16085551.001]
  • [Cites] Int J Hematol. 1997 Jun;65(4):415-6 [9195782.001]
  • [Cites] Transfus Med. 2005 Oct;15(5):445-8 [16202062.001]
  • [Cites] Eur J Haematol. 2004 Apr;72(4):264-7 [15089764.001]
  • [Cites] Int J Hematol. 2000 Dec;72(4):418-24 [11197207.001]
  • (PMID = 17562618.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Organic Chemicals; 0 / acrarubicin; 04079A1RDZ / Cytarabine; 93NS566KF7 / gemtuzumab
  •  go-up   go-down


15. Pan JL, Xue YQ, Jiang HY, He J, Wang W, Wu YF: [Application of reverse transcription-multiplex nested PCR to detect MLL rearrangement in AML-M4/M5]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Aug;22(4):444-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of reverse transcription-multiplex nested PCR to detect MLL rearrangement in AML-M4/M5].
  • OBJECTIVE: To explore the value of reverse transcription-multiplex nested PCR in detecting MLL rearrangement in lzAML-M4/M5.
  • Five common MLL fusion genes and MLL partial tandem duplication in 40 AML cases, including 12 M4 and 28 M5 were detected by reverse transcription(RT)-multiplex nested PCR.
  • CONCLUSION: RT-multiplex nested PCR is a powerful technique in the detection of MLL rearrangement for tentativelly diagnosed AML-M4/M5.
  • [MeSH-major] Leukemia, Myelomonocytic, Acute / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086288.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  •  go-up   go-down


16. Woo KS, Kim KE, Kim KH, Kim SH, Park JI, Shaffer LG, Han JY: Deletions of chromosome arms 7p and 7q in adult acute myeloid leukemia: a marker chromosome confirmed by array comparative genomic hybridization. Cancer Genet Cytogenet; 2009 Oct 15;194(2):71-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletions of chromosome arms 7p and 7q in adult acute myeloid leukemia: a marker chromosome confirmed by array comparative genomic hybridization.
  • Acute myeloid leukemia (AML) cases with monosomy 7 (-7) and del(7q) comprise a heterogeneous subgroup.
  • The association of losses in 7q with myeloid leukemia suggests that this region contains a tumor suppressor gene or genes whose loss of function contributes to leukemic transformation or tumor progression.
  • In the present case, we identified a rare abnormality involving deletion of both arms of chromosome 7 presenting with a marker chromosome-like appearance in an AML patient.
  • Bone marrow aspiration and biopsy revealed acute myelomonocytic leukemia.
  • [MeSH-major] Biomarkers, Tumor / genetics. Chromosome Deletion. Chromosomes, Human, Pair 7. Leukemia, Myeloid, Acute / genetics


17. Gutierrez JA, Pan YX, Koroniak L, Hiratake J, Kilberg MS, Richards NG: An inhibitor of human asparagine synthetase suppresses proliferation of an L-asparaginase-resistant leukemia cell line. Chem Biol; 2006 Dec;13(12):1339-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An inhibitor of human asparagine synthetase suppresses proliferation of an L-asparaginase-resistant leukemia cell line.
  • Drug resistance in lymphoblastic and myeloblastic leukemia cells is poorly understood, with several lines of evidence suggesting that resistance can be correlated with upregulation of human asparagine synthetase (hASNS) expression, although this hypothesis is controversial.
  • These observations represent direct evidence that potent hASNS inhibitors may prove to be effective agents for the clinical treatment of acute lymphoblastic leukemia.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 1999 Dec 7;38(49):16146-57 [10587437.001]
  • [Cites] Annu Rev Biochem. 2006;75:629-54 [16756505.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26 [11259830.001]
  • [Cites] Biochemistry. 2001 May 15;40(19):5655-64 [11341830.001]
  • [Cites] Biochem J. 2001 Jul 1;357(Pt 1):321-8 [11415466.001]
  • [Cites] Nat Struct Biol. 2001 Aug;8(8):689-94 [11473259.001]
  • [Cites] Biochem J. 2001 Aug 15;358(Pt 1):59-67 [11485552.001]
  • [Cites] Biochemistry. 2001 Sep 18;40(37):11168-75 [11551215.001]
  • [Cites] Annu Rev Biochem. 2001;70:149-80 [11395405.001]
  • [Cites] Methods Enzymol. 2002;354:260-71 [12418233.001]
  • [Cites] Arch Biochem Biophys. 2003 May 1;413(1):23-31 [12706338.001]
  • [Cites] Org Lett. 2003 Jun 12;5(12):2033-6 [12790521.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Sep 26;55(10):1293-302 [14499708.001]
  • [Cites] Biochemistry. 1969 Jun;8(6):2681-5 [5799144.001]
  • [Cites] J Biol Chem. 1969 Aug 10;244(15):4112-21 [4895361.001]
  • [Cites] Annu Rev Pharmacol. 1970;10:421-40 [4911021.001]
  • [Cites] Biochem Pharmacol. 1969 Oct;18(10):2578-80 [4935103.001]
  • [Cites] Cancer. 1971 Oct;28(4):819-24 [5286444.001]
  • [Cites] J Biol Chem. 1972 Oct 25;247(20):6708-19 [5076775.001]
  • [Cites] Biochem Biophys Res Commun. 1973 Apr 2;51(3):529-35 [4512981.001]
  • [Cites] J Biol Chem. 1973 Jun 10;248(11):3997-4002 [4145324.001]
  • [Cites] Biochem Pharmacol. 1975 Dec 1;24(23):2177-85 [1212266.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Anal Biochem. 1976 Dec;76(2):423-30 [11707.001]
  • [Cites] Cancer Treat Rep. 1976 Oct;60(10):1493-557 [14784.001]
  • [Cites] Cancer Treat Rep. 1979 Jun;63(6):1095-108 [38003.001]
  • [Cites] Cancer Res. 1979 Oct;39(10):3893-6 [383278.001]
  • [Cites] Methods Enzymol. 1979;63:103-38 [502857.001]
  • [Cites] Ann Occup Hyg. 1980;23(1):27-33 [6445702.001]
  • [Cites] Arch Biochem Biophys. 1985 Mar;237(2):335-46 [2858178.001]
  • [Cites] Anal Biochem. 1987 Mar;161(2):438-41 [3495203.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1988;61:201-301 [3281418.001]
  • [Cites] Anal Biochem. 1988 Apr;170(1):220-7 [3389513.001]
  • [Cites] Leukemia. 1989 Apr;3(4):294-7 [2564453.001]
  • [Cites] Biochemistry. 1990 Jan 16;29(2):366-72 [1967948.001]
  • [Cites] J Comput Aided Mol Des. 1990 Mar;4(1):1-105 [2197373.001]
  • [Cites] Biochemistry. 1991 Jun 25;30(25):6135-41 [1676298.001]
  • [Cites] J Comput Aided Mol Des. 1991 Feb;5(1):55-80 [2072126.001]
  • [Cites] Anal Biochem. 1991 May 1;194(2):268-77 [1677799.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1992 May;14(2):136-9 [1530118.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1993;66:203-309 [8430515.001]
  • [Cites] Biochemistry. 1994 Jan 25;33(3):675-81 [7904828.001]
  • [Cites] J Biol Chem. 1994 Mar 11;269(10):7450-7 [7907328.001]
  • [Cites] J Biol Chem. 1994 Oct 28;269(43):26789-95 [7929415.001]
  • [Cites] Biol Pharm Bull. 1996 Nov;19(11):1518-20 [8951178.001]
  • [Cites] Am J Physiol. 1997 May;272(5 Pt 1):C1691-9 [9176161.001]
  • [Cites] Nat Struct Biol. 1998 Jan;5(1):15-9 [9437423.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1998;72:87-144 [9559052.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1998;72:145-98 [9559053.001]
  • [Cites] Biochemistry. 1998 Sep 22;37(38):13230-8 [9748330.001]
  • [Cites] Bioorg Med Chem. 1998 Oct;6(10):1935-53 [9839023.001]
  • [Cites] Biochemistry. 1999 Mar 23;38(12):3677-82 [10090755.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):291-9 [15665306.001]
  • [Cites] Curr Opin Chem Biol. 2005 Feb;9(1):25-30 [15701449.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4223-5 [15718422.001]
  • [Cites] Arch Biochem Biophys. 2005 Aug 1;440(1):18-27 [16023613.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2005;6:261-86 [16124862.001]
  • [Cites] Br J Haematol. 2006 Mar;132(6):740-2 [16487174.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4244-9 [16497975.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7975-9 [10713115.001]
  • (PMID = 17185229.001).
  • [ISSN] 1074-5521
  • [Journal-full-title] Chemistry & biology
  • [ISO-abbreviation] Chem. Biol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK052064; United States / NIDDK NIH HHS / DK / R01 DK059315; United States / NIDDK NIH HHS / DK / DK52064; United States / NIDDK NIH HHS / DK / DK59315
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids, Sulfur; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; EC 3.5.1.1 / Asparaginase; EC 6.3.1.1 / Aspartate-Ammonia Ligase
  • [Other-IDs] NLM/ NIHMS447417; NLM/ PMC3608209
  •  go-up   go-down


18. Ng KP, Soo-Hoo TS, Na SL, Tay ST, Hamimah H, Lim PC, Chong PP, Seow HF, Chavez AJ, Messer SA: The mycological and molecular study of Hortaea werneckii isolated from blood and splenic abscess. Mycopathologia; 2005 Jun;159(4):495-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the isolation of H. werneckii from blood and splenic abscess of two patients with acute myelomonocytic leukaemia. H. werneckii grew at room temperature but not at 37 degrees C, it was identified by biochemical tests, growth characteristics and the presence of conspicuous collarette intercalary on dividing yeast cells.
  • [MeSH-major] Fungemia / microbiology. Leukemia, Myelomonocytic, Acute / microbiology. Mitosporic Fungi / genetics. Mitosporic Fungi / isolation & purification. Splenic Diseases / microbiology

  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 1999 Aug;29(2):239-44 [10476719.001]
  • [Cites] Diagn Microbiol Infect Dis. 2003 Jun;46(2):89-93 [12812723.001]
  • [Cites] Ophthalmic Surg Lasers. 2000 Sep-Oct;31(5):417-22 [11011711.001]
  • [Cites] Int J Dermatol. 1989 Jan-Feb;28(1):46-8 [2917812.001]
  • [Cites] Nihon Ishinkin Gakkai Zasshi. 2002;43(3):175-80 [12145633.001]
  • [Cites] Diagn Microbiol Infect Dis. 1988 Apr;9(4):231-7 [3180708.001]
  • (PMID = 15983734.001).
  • [ISSN] 0301-486X
  • [Journal-full-title] Mycopathologia
  • [ISO-abbreviation] Mycopathologia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Fungal
  •  go-up   go-down


19. Tarkun P, Hacıhanefioğlu A, Demirbağ E, Turgut T: Development of autoimmune hemolytic anemia during the treatment of a patient with acute myelomonocytic leukemia. Turk J Haematol; 2005 Jun 5;22(2):95-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of autoimmune hemolytic anemia during the treatment of a patient with acute myelomonocytic leukemia.
  • [Transliterated title] Akut miyelomonositik lösemili bir hastanın tedavisi srasında ortaya çıkan otoimmün hemolitik anemi.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27264668.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


20. Mozziconacci MJ, Carbuccia N, Prebet T, Charbonnier A, Murati A, Vey N, Chaffanet M, Birnbaum D: Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110-FGFR1 fusion: report of a new case and review of the literature. Leuk Res; 2008 Aug;32(8):1304-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 8p12 myeloproliferative syndrome is a rare, generally aggressive chronic myeloproliferative disorder (MPD).
  • We report here the tenth case of translocation (8;9)(p12;q33) in an acute myelomonocytic leukemia and provide a review of the literature that points to common syndrome features: the t(8;9)(p11;q33) MPD transforms rapidly, and always in myelomonocytic leukemia, with a possible B- or T-lymphoid involvement, which may include tonsil invasion.
  • [MeSH-major] Chromosomes, Human, Pair 8. Chromosomes, Human, Pair 9. Leukemia, Myelomonocytic, Acute / genetics. Myeloproliferative Disorders / genetics. Oncogene Proteins, Fusion / metabolism. Receptor, Fibroblast Growth Factor, Type 1 / metabolism. Translocation, Genetic

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18096225.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1; EC 2.7.11.- / CEP110-FGFR1 fusion protein, human
  • [Number-of-references] 14
  •  go-up   go-down


21. Eliashar R, Resnick IB, Goldfarb A, Wohlgelernter J, Gross M: Endoscopic surgery for sinonasal invasive aspergillosis in bone marrow transplantation patients. Laryngoscope; 2007 Jan;117(1):78-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Demographic data, primary disease, comorbidities, signs and symptoms, blood test results, preparation for surgery, surgical technique, and outcome were recorded.
  • The primary disease was acute myelogenous leukemia in 6, acute lymphoblastic leukemia in 3, chronic myeloblastic leukemia in one, severe combined immunodeficiency disease in 2, and myelodysplastic syndrome in 2 patients.
  • Diagnosis was made by physical examination, biopsy, culture, and computed tomography scan.
  • Six patients died of the primary illness or of comorbidities with no evidence of residual disease.
  • CONCLUSION: Early detection of IA in BMT patients enables aggressive treatment before the disease spreads into the orbit or brain.
  • [MeSH-major] Aspergillosis / surgery. Bone Marrow Transplantation / adverse effects. Endoscopy / methods. Leukemia / complications. Opportunistic Infections / surgery. Paranasal Sinus Diseases / surgery


22. Sino US Leukemia Cooperative Group of Shanghai: [Clinical study of 572 adult acute leukemia patients in Shanghai according to WHO classification]. Zhonghua Xue Ye Xue Za Zhi; 2007 Jul;28(7):444-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of 572 adult acute leukemia patients in Shanghai according to WHO classification].
  • OBJECTIVE: To evaluate WHO classification of acute leukemia (AL) in Shanghai and compare the difference between WHO and FAB classification.
  • METHODS: Successive and unselected leukemia patients were referred to Sino-US Leukemia Cooperative Group of Shanghai from 2003 to 2006.
  • A total of 572 adult AL cases were diagnosed and classified according to WHO and FAB classification.
  • RESULTS: Of the 572 AL patients, 436 (76.2%) were diagnosed as acute myeloid leukemia (AML), 119 (20.8%) acute lymphoblastic leukemia (ALL).
  • The AML and ALL percentage ratio was 3.66: 1.
  • AML with recurrent cytogenetic abnormalities accounted for 35.3%, and with multilineage dysplasia for 13.1%, therapy-related AML accounted for 0.9%, and AML not otherwise categorized for 50.7%.
  • The percentage of therapy-related AML in Shanghai was lower than that in the Western.
  • According to FAB classification, AML-M4 was the most (38.5%) common subtype.
  • The percentage of AML-M3 and M4 in Shanghai were higher than that in the Western, but that of AML-M, was lower.
  • The incidence of karyotypic abnormalities in AML was 60.8%.
  • The incidence of AML with t (15;17) was higher than that in the Western.
  • Favorable cytogenetic risk group accounted for 30.6%, intermediate group for 51.5%, unfavorable group for 17.9% of AML.
  • CONCLUSIONS: The percentages of AML with t (15;17) and AML-M4 in Shanghai and the incidence of cytogenetic favorable group were higher than that in the Western.
  • It was different in WHO classification and karyotypic abnormalities of AML between Shanghai and the Western.
  • Comparing to the AL data of Shanghai Leukemia Group between 1984 and 1994, the percentage of AML-M4 was increased, but that of AML-M1 and M5 were decreased.
  • [MeSH-major] Leukemia / classification
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. China. Female. Humans. Karyotyping. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18072625.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Harani MS, Adil SN, Shaikh MU, Kakepoto GN, Khurshid M: Frequency of fab subtypes in acute myeloid leukemia patients at Aga Khan University Hospital Karachi. J Ayub Med Coll Abbottabad; 2005 Jan-Mar;17(1):26-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of fab subtypes in acute myeloid leukemia patients at Aga Khan University Hospital Karachi.
  • BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous disease.
  • Therefore, various parameters are needed to classify this disease into subtypes, so that specific treatment approaches can be utilized effectively.
  • The commonly used method for diagnosis and classification is based on FAB criteria using morphology and cytochemical stains.
  • The aim of present study is to determine the frequency of various sub types in acute myeloid leukemia using FAB criteria in our population.
  • This will aid in the correct diagnosis of acute leukemia and hence proper management of the patients.
  • The patients were diagnosed on the basis of bone marrow morphology using FAB classification.
  • AML-M4 was the predominant French-American-British (FAB) subtype (36.2%) followed by M2 (30.25%), M3 (10.4%), M1 (8.7%), M0 (7.7%), M5a (3.5%), M5b (2.5%) and M6 (0.8%).
  • CONCLUSIONS: The most common FAB subtype observed in our study was Acute myelomonocytic leukemia (M4) which is in accordance with studies reported from Saudia Arabia and a previous study reported from our institution.
  • However,other national and international studies have reported Myeloblastic Leukemia with maturation (M2) as the predominant subtype of AML.
  • [MeSH-major] Leukemia, Myeloid / classification
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Child. Child, Preschool. Female. Hospitals, University. Humans. Infant. Male. Middle Aged. Pakistan

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929522.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


24. Shimizu T, Kuromi A, Takeda K: Synergistic induction of gene expression during the differentiation into mature macrophage in human myeloblastic leukemia cells treated with TPA and KH1060. Leuk Res; 2009 Jun;33(6):803-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic induction of gene expression during the differentiation into mature macrophage in human myeloblastic leukemia cells treated with TPA and KH1060.
  • Treatment of human myeloblastic leukemia ML-1 cells with the phorbol ester TPA in combination with the vitamin D(3) analogue KH1060 will induce a synergistic differentiation to mature macrophage with multinuclei.
  • [MeSH-major] Calcitriol / analogs & derivatives. Cell Differentiation. Gene Expression Regulation / drug effects. Leukemia, Myeloid, Acute / pathology. Macrophages / cytology. Tetradecanoylphorbol Acetate / pharmacology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19144406.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 131875-08-6 / KH 1060; FXC9231JVH / Calcitriol; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


25. Blatt J, Greenwood R, Weig S, Rao K, Fedoriw GD, Dent G: Isolated central nervous system relapse in an adolescent with acute myelomonocytic leukemia, Charcot Marie Tooth syndrome, and paraneoplastic autoantibody. J Pediatr Hematol Oncol; 2010 Oct;32(7):571-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated central nervous system relapse in an adolescent with acute myelomonocytic leukemia, Charcot Marie Tooth syndrome, and paraneoplastic autoantibody.
  • A 17-year-old boy, with acute myelomonocytic leukemia and inversion 16(p13q22) developed polyneuropathy and isolated central nervous system relapse.
  • Scoliosis and high-arched feet suggested a diagnosis of Charcot Marie Tooth (CMT) syndrome and genetic testing confirmed duplication at the PMP22 locus at chromosome 17p11.12.
  • This case extends the clinical spectrum of cancer with CMT, and of paraneoplastic disorders.
  • [MeSH-major] Autoantibodies / blood. Charcot-Marie-Tooth Disease / immunology. Leukemia, Myelomonocytic, Acute / immunology. Paraneoplastic Syndromes, Nervous System / immunology

  • Genetic Alliance. consumer health - Acute Myelomonocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Charcot-Marie-Tooth Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20724950.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Myelin Proteins; 0 / PMP22 protein, human
  •  go-up   go-down


26. Otsubo K, Kanegane H, Eguchi M, Eguchi-Ishimae M, Tamura K, Nomura K, Abe A, Ishii E, Miyawaki T: ETV6-ARNT fusion in a patient with childhood T lymphoblastic leukemia. Cancer Genet Cytogenet; 2010 Oct 1;202(1):22-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ETV6-ARNT fusion in a patient with childhood T lymphoblastic leukemia.
  • Leukemia with t(1;12)(q21;p13) was previously described in a 5-year-old boy with acute myeloblastic leukemia (AML-M2) who exhibited a novel ETV6-aryl hydrocarbon receptor nuclear translocator (ARNT) fusion protein.
  • We herein report the case of a 2-year-old boy with T-cell lymphoblastic leukemia (T-ALL) harboring t(1;12)(q21;p13).
  • The ETV6-ARNT fusion is associated not only with AML but also with T-ALL.
  • [MeSH-major] ARNTL Transcription Factors / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20804916.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ARNTL Transcription Factors; 0 / DNA Primers; 0 / ETS translocation variant 6 protein; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins
  •  go-up   go-down


27. Park TS, Lee ST, Song J, Lee KA, Lee JH, Kim J, Lee HJ, Han JH, Kim JK, Cho SR, Choi JR: Detection of a novel CBFB/MYH11 variant fusion transcript (K-type) showing partial insertion of exon 6 of CBFB gene using two commercially available multiplex RT-PCR kits. Cancer Genet Cytogenet; 2009 Mar;189(2):87-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of a novel CBFB/MYH11 variant fusion transcript (K-type) showing partial insertion of exon 6 of CBFB gene using two commercially available multiplex RT-PCR kits.
  • We report on a 20-year-old man with acute myeloid leukemia (AML) showing a distinct novel CBFB/MYH11 variant fusion transcript.
  • Initial results of bone marrow, chromosome, and flow cytometric analyses were not in accordance with the diagnosis of acute myelomonocytic leukemia with eosinophilia (AML-M4Eo) or AML with a CBFB/MYH11 rearrangement.
  • Not only does this case show a partial insertion of exon 6 of the CBFB (ENSG00000067955) gene, but it also involves novel breakpoints within both exon 6 of the CBFB gene and exon 28 (previously exon 7) of the MYH11 (ENSG00000133392) gene, which is regarded as a previously non-reported, new type (K-type) of CBFB/MYH11 fusion transcript.
  • Therefore, multiplex RT-PCR and sequence analysis of these atypical products should be performed to diagnose atypical AML with CBFB/MYH11 rearrangement, to predict prognosis of these patients as well as to elucidate the molecular mechanism.
  • [MeSH-major] Core Binding Factor beta Subunit / genetics. Leukemia, Myeloid, Acute / genetics. Mutagenesis, Insertional. Myosin Heavy Chains / genetics. Reagent Kits, Diagnostic. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215788.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CBFB protein, human; 0 / Core Binding Factor beta Subunit; 0 / MYH11 protein, human; 0 / Reagent Kits, Diagnostic; 0 / Recombinant Fusion Proteins; EC 3.6.4.1 / Myosin Heavy Chains
  •  go-up   go-down


28. Chou CY, Chien CH, Han YS, Prebanda MT, Hsieh HP, Turk B, Chang GG, Chen X: Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus. Biochem Pharmacol; 2008 Apr 15;75(8):1601-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus.
  • The papain-like protease of severe acute respiratory syndrome coronavirus (PLpro) (EC 3.4.22.46) is essential for the viral life cycle and therefore represents an important antiviral target.
  • Both 6MP and 6TG are still used extensively in clinics, especially for children with acute lymphoblastic or myeloblastic leukemia.

  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313035.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protease Inhibitors; 0 / Viral Proteins; E7WED276I5 / 6-Mercaptopurine; EC 3.4.22.- / 3C-like protease, SARS coronavirus; EC 3.4.22.- / Cysteine Endopeptidases; FTK8U1GZNX / Thioguanine
  •  go-up   go-down


29. Dăscălescu A, Zlei M, Grigore G, Dănăila C, Jitaru D, Carasevici E: [Prognostic significance of leukemia-associated phenotype in correlation with other biologic markers in acute myeloid leukemia patients]. Rev Med Chir Soc Med Nat Iasi; 2009 Oct-Dec;113(4):1176-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic significance of leukemia-associated phenotype in correlation with other biologic markers in acute myeloid leukemia patients].
  • Leukemic cells have unique aberrant phenotypes, which permit identification of this cells at diagnose and in evolution of the disease.
  • The main aim of the current study is to identify correlation between recognized prognostic factors in acute myeloid leukemia (AML) patients and other phenotypic markers.
  • MATERIAL AND METHOD: Imunophenotypic analysis (BDFACS CantoII, FACSDiva Software) was performed on peripheral blood/bone marrow aspirate samples of 56 patients diagnosed with AML (9 M0, 3 M1, 10 M2, 4 M3, 28 M4/M5, 1 M6, 1 M7) between 2007-2009 in Hematology Department of "Sf.
  • RESULTS: In our study, IL7R expression on AML blasts was significant correlate with low WBC count at diagnosis (p = 0.04) and with multilinear displasia (p = 0.01), high CXCR4 expression was correlate (p = 0.05) with lack of response at first induction therapy and CD123 (IL3Ra) expression was correlate with M4 FAB phenotype.
  • Survival was negative influenced by presence of IL3R on AML blasts, but flt3 mutations, CXCR4, IL7R expression on leukemic cells, other phenotypic aberrancies did not influenced treatment response and survival in our patients population.
  • CONCLUSION: Complete investigation of leukemic cells phenotype extended with cytokines/chemokines receptors at diagnostic is useful for correct characterization of the disease, for discover new prognostic categories and for better identification of minimal residual disease.
  • [MeSH-major] Biomarkers, Tumor / blood. Leukemia, Myeloid, Acute / immunology. Receptors, Chemokine / blood. Receptors, Cytokine / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Phenotype. Predictive Value of Tests. Prognosis. Receptors, CCR5 / blood. Receptors, CXCR4 / blood. Receptors, Interleukin-3 / blood. Receptors, Interleukin-7 / blood. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20191895.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, CCR5; 0 / Receptors, CXCR4; 0 / Receptors, Chemokine; 0 / Receptors, Cytokine; 0 / Receptors, Interleukin-3; 0 / Receptors, Interleukin-7
  •  go-up   go-down


30. Astashkin EI, Suvorov NI, Mikhailova AA, Grachev SV: Change in the Ca2+ response to formyl peptide in HL-60 myeloblastic leukemia cells after the induction of their differentiation by MP-4 myelogenic peptide. Dokl Biol Sci; 2006 May-Jun;408:265-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Change in the Ca2+ response to formyl peptide in HL-60 myeloblastic leukemia cells after the induction of their differentiation by MP-4 myelogenic peptide.
  • [MeSH-major] Calcium / metabolism. Leukemia, Promyelocytic, Acute / drug therapy. Oligopeptides / therapeutic use

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Jun 15;93(12):4395-405 [10361138.001]
  • [Cites] Biochem Pharmacol. 1998 Oct 15;56(8):1023-7 [9776313.001]
  • [Cites] FEBS Lett. 2000 Mar 31;470(3):281-4 [10745082.001]
  • [Cites] Biochem Pharmacol. 2000 Apr 15;59(8):947-51 [10692559.001]
  • [Cites] Dokl Akad Nauk. 1998 Jan;358(1):134-6 [9551320.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2427-33 [11290607.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1325-32 [12649194.001]
  • [Cites] Biochem Pharmacol. 2000 Jul 15;60(2):179-87 [10825462.001]
  • (PMID = 16909995.001).
  • [ISSN] 0012-4966
  • [Journal-full-title] Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections
  • [ISO-abbreviation] Dokl. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligopeptides; 0 / phenylalanyl-arginyl-prolyl-arginyl-isoleucyl-methionyl-threonyl-proline; 137833-32-0 / myelopeptides; 59880-97-6 / N-Formylmethionine Leucyl-Phenylalanine; SY7Q814VUP / Calcium
  •  go-up   go-down


31. Pânzaru C, Dan M, Burcoveanu C, Mereuţă A, Buiuc D: Disseminated infection due to Candida guilliermondii in a patient with AML(M4). Case study. Rev Med Chir Soc Med Nat Iasi; 2006 Jul-Sep;110(3):727-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated infection due to Candida guilliermondii in a patient with AML(M4). Case study.
  • A 43-year-old patient admitted with acute myelogenous leukemia, developed bronchopneumonia and sepsis during profound neutropenia.
  • After a few days of therapy with Voriconazol, fever disappeared and the clinical state of patient was improved.
  • [MeSH-major] Candida / isolation & purification. Candidiasis / complications. Fungemia / microbiology. Immunocompromised Host. Leukemia, Myeloid, Acute / complications

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17571574.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; 7XU7A7DROE / Amphotericin B; 8VZV102JFY / Fluconazole; JFU09I87TR / Voriconazole
  •  go-up   go-down


32. Shen M, Yen A: c-Cbl tyrosine kinase-binding domain mutant G306E abolishes the interaction of c-Cbl with CD38 and fails to promote retinoic acid-induced cell differentiation and G0 arrest. J Biol Chem; 2009 Sep 18;284(38):25664-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Retinoic acid (RA) causes HL-60 human myeloblastic leukemia cell myeloid differentiation that is dependent on MAPK signaling.
  • Unlike wild-type (WT) c-Cbl, the G306E mutant c-Cbl fails to propel RA-induced differentiation, and disrupts the normal association with CD38.

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Oct 29;274(44):31707-12 [10531381.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8761-9 [18974118.001]
  • [Cites] J Biol Chem. 2000 Jan 7;275(1):414-22 [10617633.001]
  • [Cites] Biochem J. 2000 Jan 15;345 Pt 2:385-92 [10620516.001]
  • [Cites] J Immunol. 2000 May 1;164(9):4616-26 [10779765.001]
  • [Cites] Cell. 2000 Aug 18;102(4):533-9 [10966114.001]
  • [Cites] Leuk Res. 2001 Jan;25(1):1-12 [11137554.001]
  • [Cites] J Cell Biol. 2001 Jan 8;152(1):181-95 [11149930.001]
  • [Cites] Eur J Cell Biol. 2001 Jan;80(1):59-67 [11211936.001]
  • [Cites] Cell Growth Differ. 2001 Apr;12(4):193-200 [11331248.001]
  • [Cites] Ann Hematol. 2001 Jul;80(7):417-22 [11529468.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):13-22 [11689561.001]
  • [Cites] Mol Cancer Ther. 2002 May;1(7):493-506 [12479267.001]
  • [Cites] J Exp Med. 2003 Feb 17;197(4):503-13 [12591907.001]
  • [Cites] Cell Mol Life Sci. 2003 Sep;60(9):1805-27 [14523545.001]
  • [Cites] J Exp Med. 2004 Jul 5;200(1):25-34 [15238603.001]
  • [Cites] Nature. 1977 Nov 24;270(5635):347-9 [271272.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 May;77(5):2936-40 [6930676.001]
  • [Cites] Blood. 1988 Jan;71(1):242-7 [3422031.001]
  • [Cites] Blood. 1991 Apr 1;77(7):1418-22 [1849030.001]
  • [Cites] Oncogene. 1992 Jun;7(6):1083-91 [1594241.001]
  • [Cites] Biochem J. 1992 Dec 1;288 ( Pt 2):351-5 [1334404.001]
  • [Cites] J Biol Chem. 1995 Jun 2;270(22):13246-53 [7768923.001]
  • [Cites] Science. 1995 Nov 24;270(5240):1326-31 [7481820.001]
  • [Cites] Blood. 1996 Jan 1;87(1):227-37 [8547646.001]
  • [Cites] J Biol Chem. 1996 Jan 19;271(3):1534-7 [8576149.001]
  • [Cites] J Biol Chem. 1996 Apr 5;271(14):8435-42 [8626543.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1161-6 [9064333.001]
  • [Cites] Immunity. 1997 Feb;6(2):155-64 [9047237.001]
  • [Cites] J Immunol. 1997 Jul 1;159(1):70-6 [9200440.001]
  • [Cites] Oncogene. 1997 Nov 20;15(21):2511-20 [9399639.001]
  • [Cites] Int J Biochem Cell Biol. 1998 Apr;30(4):439-44 [9675877.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3163-72 [9679985.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1697-706 [9716598.001]
  • [Cites] Cell Signal. 1998 Jun;10(6):377-85 [9720760.001]
  • [Cites] FEBS Lett. 1998 Dec 28;441(3):480-4 [9891995.001]
  • [Cites] Nature. 1999 Mar 4;398(6722):84-90 [10078535.001]
  • [Cites] Oncogene. 1999 Jun 10;18(23):3440-51 [10376522.001]
  • [Cites] Science. 1999 Oct 8;286(5438):309-12 [10514377.001]
  • [Cites] Exp Cell Res. 2005 Dec 10;311(2):281-93 [16246327.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Dec;6(12):907-18 [16227975.001]
  • [Cites] J Cell Biochem. 2006 Apr 15;97(6):1328-38 [16329108.001]
  • [Cites] Mol Cell. 2006 Jun 23;22(6):851-68 [16793553.001]
  • [Cites] J Cell Physiol. 2006 Oct;209(1):21-43 [16741904.001]
  • [Cites] Methods. 2006 Dec;40(4):353-9 [17101448.001]
  • [Cites] EMBO J. 2006 Dec 13;25(24):5683-92 [17139251.001]
  • [Cites] Am J Pathol. 2007 Jan;170(1):176-87 [17200192.001]
  • [Cites] Nat Cell Biol. 2007 Mar;9(3):324-30 [17310240.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3352-9 [17684154.001]
  • [Cites] J Biol Chem. 2008 Feb 15;283(7):4375-86 [18006504.001]
  • [Cites] EMBO J. 2008 Mar 5;27(5):804-16 [18273061.001]
  • [Cites] Hematology. 2007 Oct;12(5):409-14 [17852458.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1999 Oct;35(9):527-32 [10548434.001]
  • (PMID = 19635790.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antineoplastic Agents; 0 / Membrane Glycoproteins; 0 / Multiprotein Complexes; 0 / Phosphoproteins; 0 / Proto-Oncogene Proteins c-vav; 0 / SLP-76 signal Transducing adaptor proteins; 5688UTC01R / Tretinoin; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human; EC 6.3.2.- / CBL protein, human; EC 6.3.2.- / Proto-Oncogene Proteins c-cbl
  • [Other-IDs] NLM/ PMC2757968
  •  go-up   go-down


33. Steinherz PG, Shukla N, Kobos R, Steinherz L: Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. Pediatr Blood Cancer; 2010 May;54(5):687-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
  • BACKGROUND: We determined the maximum tolerated dose (MTD) of clofarabine when administered with topotecan, vinorelbine, thiotepa, and dexamethasone (TVTC) for children with relapsed or refractory acute leukemia, and observed the efficacy and toxicities of this therapy.
  • PROCEDURE: Twelve patients with acute lymphoblastic or myeloblastic leukemia were given a 14-day remission induction therapy.
  • Three patients had progressive disease.
  • One patient died on day 45 with marrow hypoplasia without evidence of leukemia.
  • CONCLUSION: TVTC has significant anti-leukemic activity in both acute lymphoblastic and myeloblastic leukemia.
  • This is the recommended dose for the phase II study in patients with refractory or relapsed leukemia, a population which has limited therapeutic options.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205253.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 5V9KLZ54CY / Vinblastine; 762RDY0Y2H / clofarabine; 7M7YKX2N15 / Topotecan; 905Z5W3GKH / Thiotepa; Q6C979R91Y / vinorelbine
  •  go-up   go-down


34. Yen A, Varvayanis S, Smith JL, Lamkin TJ: Retinoic acid induces expression of SLP-76: expression with c-FMS enhances ERK activation and retinoic acid-induced differentiation/G0 arrest of HL-60 cells. Eur J Cell Biol; 2006 Feb;85(2):117-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Retinoic acid (RA) is known to cause MAPK signaling which propels G0 arrest and myeloid differentiation of HL-60 human myeloblastic leukemia cells.
  • A triple Y to F mutant SLP-76 known to be a dominant negative in T-cell receptor signaling failed to enhance RA-induced paxillin expression, but enhanced RA-induced ERK activation, differentiation and G0 arrest essentially as well as wild-type SLP-76.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Blotting, Western. Enzyme Activation. HL-60 Cells. Humans. Immunoprecipitation. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / physiopathology. Mutation. Paxillin / genetics. Paxillin / physiology. Phosphorylation. Receptors, Antigen, T-Cell / physiology. Signal Transduction. Superoxides / metabolism. Transfection. Up-Regulation / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16439309.001).
  • [ISSN] 0171-9335
  • [Journal-full-title] European journal of cell biology
  • [ISO-abbreviation] Eur. J. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Paxillin; 0 / Phosphoproteins; 0 / Receptors, Antigen, T-Cell; 0 / SLP-76 signal Transducing adaptor proteins; 11062-77-4 / Superoxides; 5688UTC01R / Tretinoin; EC 2.7.10.1 / Receptor, Macrophage Colony-Stimulating Factor; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


35. Lamkin TJ, Chin V, Varvayanis S, Smith JL, Sramkoski RM, Jacobberger JW, Yen A: Retinoic acid-induced CD38 expression in HL-60 myeloblastic leukemia cells regulates cell differentiation or viability depending on expression levels. J Cell Biochem; 2006 Apr 15;97(6):1328-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoic acid-induced CD38 expression in HL-60 myeloblastic leukemia cells regulates cell differentiation or viability depending on expression levels.
  • Retinoic acid-induced expression of the CD38 ectoenzyme receptor in HL-60 human myeloblastic leukemia cells is regulated by RARalpha and RXR, and enhanced or prevented cell differentiation depending on the level of expression per cell.
  • Expression of CD38 enhanced retinoic acid-induced myeloid differentiation and G0 cell cycle arrest, but at higher expression levels, induced differentiation was blocked and retinoic acid induced a loss of cell viability instead.
  • In the case of 1,25-dihydroxyvitamin D3, induced monocytic differentiation was also enhanced by CD38 and not enhanced by higher expression levels, but without induced loss of viability.
  • [MeSH-major] Antigens, CD38 / metabolism. Cell Differentiation / drug effects. Cell Survival / drug effects. Leukemia, Myeloid, Acute / metabolism. Tretinoin / pharmacology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16329108.001).
  • [ISSN] 0730-2312
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / T32 ES007052
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Retinoic Acid; 0 / Retinoid X Receptors; 0 / retinoic acid receptor alpha; 5688UTC01R / Tretinoin; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


36. Forestier E, Schmiegelow K, Nordic Society of Paediatric Haematology and Oncology NOPHO: The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations. J Pediatr Hematol Oncol; 2006 Aug;28(8):486-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations.
  • The correlation between age and karyotype was studied in 1425, 0 to 14.9 years old children who were diagnosed with acute lymphoblastic leukemia (ALL) or acute myeloblastic leukemia.
  • Among B-cell precursor ALL cases, high white blood cell counts correlated with earlier age at diagnosis (rS=-0.23; P<0.001) being most evident for 11q23/MLL-aberrations, translocation t(12;21)(p13;q22), and high-hyperdiploidy.
  • Among acute myeloblastic leukemia patients, frequency peaks were found for those with MLL/11q23 rearrangements (peak: first year), Down syndrome (peak: second to third year), or cytogenetic abnormalities other than translocations t(8;21), t(15;17), and inv(16)/t(16;16) (peak: first to third year).
  • The epidemiology of the cytogenetic subsets of acute leukemias questions whether age as a disease-related prognostic parameter has any relevance in childhood leukemia clinical research beyond being a surrogate marker for more important, truly biologic features such as cytogenetic aberrations and white cell count at diagnosis.
  • Further research is needed to explore whether the 2 to 7 years age incidence peak in childhood ALL harbor yet unidentified cytogenetic subsets with the same natural history as the high-hyperdiploid and t(12;21)-positive leukemias.
  • [MeSH-major] Chromosome Aberrations. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Age Distribution. Child. Child, Preschool. Cohort Studies. Comorbidity. Cytogenetic Analysis / methods. Down Syndrome / diagnosis. Down Syndrome / epidemiology. Down Syndrome / genetics. Female. Humans. Incidence. Infant. Infant, Newborn. Karyotyping. Male. Ploidies. Recurrence. Registries / statistics & numerical data. Risk Factors. Scandinavian and Nordic Countries / epidemiology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912588.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Mylonakis ME, Petanides TA, Valli VE, Vernau W, Koytinas AF, Michael RS: Acute myelomonocytic leukaemia with short-term spontaneous remission in a cat. Aust Vet J; 2008 Jun;86(6):224-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelomonocytic leukaemia with short-term spontaneous remission in a cat.
  • A complete blood count (CBC) and a biochemistry profile showed leukocytosis, numerous blast cells in the peripheral blood, thrombocytopenia, hyperglobulinaemia and a positive test for feline leukaemia virus antigen.
  • A diagnosis of acute myelomonocytic leukaemia was made on the basis of the results of bone marrow cytology, histopathology, and immunochemistry (CD3, CD79a, lysozyme, and myeloperoxidase) tests.
  • Following an unexpected 1-month period of clinical and clinicopathological remission without chemotherapy, the cat relapsed and died 1 week later.
  • [MeSH-major] Cat Diseases / diagnosis. Leukemia, Myelomonocytic, Acute / veterinary. Neoplasm Regression, Spontaneous

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18498558.001).
  • [ISSN] 0005-0423
  • [Journal-full-title] Australian veterinary journal
  • [ISO-abbreviation] Aust. Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


38. Mansoor S, Nasir-Ud-Din, Azam M, Jamshed A: Generalized cutaneous granulocytic sarcoma with joint involvement. J Coll Physicians Surg Pak; 2010 May;20(5):339-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generalized cutaneous granulocytic sarcoma with joint involvement.
  • Granulocytic sarcoma (GS) is a rare extra medullary solid tumour composed of immature myeloid cells.
  • We report a case of generalized cutaneous granulocytic sarcoma with ankle joint involvement who subsequently developed AML-M4.
  • [MeSH-major] Ankle Joint. Leukemia, Myeloid, Acute / pathology. Sarcoma / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20642930.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


39. Koga Y, Matsuzaki A, Suminoe A, Washitoh N, Hara T, Hara T, Tajiri T, Taguchi T: Treatment-related acute myelomonocytic leukemia with t(11;19) in a child following chemotherapy for hepatoblastoma. Pediatr Blood Cancer; 2008 Apr;50(4):943-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment-related acute myelomonocytic leukemia with t(11;19) in a child following chemotherapy for hepatoblastoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hepatoblastoma / drug therapy. Leukemia, Myelomonocytic, Acute / chemically induced. Liver Neoplasms / drug therapy. Neoplasms, Second Primary / chemically induced. Translocation, Genetic


40. Yan Q, Jiang Z, Yang S, Deng W, Han L: A novel homodimeric lectin from Astragalus mongholicus with antifungal activity. Arch Biochem Biophys; 2005 Oct 1;442(1):72-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A novel lectin (AMML) was isolated from a Chinese herb, i.e., the roots of Astragalus mongholicus, using a combination of ammonium sulfate fraction and ion exchange chromatographies.
  • The molecular mass of intact AMML was determined to be 66,396 Da by MALDI-TOF mass spectrometry and 61.8 kDa by gel filtration, respectively.
  • AMML was a dimeric protein composed of two identical subunits each with a molecular mass of 29.6 kDa.
  • N-terminal amino acid sequence of AMML was determined as ESGINLQGDATLANN.

  • MedlinePlus Health Information. consumer health - Molds.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. Ammonium sulfate .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140255.001).
  • [ISSN] 0003-9861
  • [Journal-full-title] Archives of biochemistry and biophysics
  • [ISO-abbreviation] Arch. Biochem. Biophys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Blood Group Antigens; 0 / Glycoproteins; 0 / Lectins; SU46BAM238 / Ammonium Sulfate; X2RN3Q8DNE / Galactose
  •  go-up   go-down


41. Struhal W, Oberndorfer S, Lahrmann H, Lindeck-Pozza E, Hess B, Nussgruber V, Pöhnl R, Dobner T, Grisold W: Myeloid sarcoma in the central nervous system: case report and review of the literature. Acta Clin Croat; 2008 Mar;47(1):19-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid sarcoma in the central nervous system: case report and review of the literature.
  • Myeloid sarcomas are rare manifestations of mainly myeloblastic leukemia.
  • A case is added herewith and a review was performed to investigate clinical characteristics and treatment options of central nervous system myeloid sarcoma.
  • A 61-year-old female with acute myeloblastic leukemia (FAB M5) and progressive left sided hemiparesis showed a right parieto-occipital epidural lesion mimicking meningioma.
  • Partial resection was performed to reveal a myeloid sarcoma.
  • Reviewing the literature we identified 44 cases with sufficient description of the diagnosis, treatment and follow up to one year.
  • [MeSH-major] Brain Neoplasms / diagnosis. Leukemia, Myeloid, Acute / diagnosis. Neoplasms, Multiple Primary. Occipital Lobe. Parietal Lobe. Sarcoma, Myeloid / diagnosis

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18714643.001).
  • [ISSN] 0353-9466
  • [Journal-full-title] Acta clinica Croatica
  • [ISO-abbreviation] Acta Clin Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 20
  •  go-up   go-down


42. Kiss F, Simon A, Csáthy L, Hevessy Z, Katona E, Kiss C, Kappelmayer J: A coagulation factor becomes useful in the study of acute leukemias: studies with blood coagulation factor XIII. Cytometry A; 2008 Mar;73(3):194-201
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A coagulation factor becomes useful in the study of acute leukemias: studies with blood coagulation factor XIII.
  • By using 3- and 4-color flow cytometry FXIII expression was investigated in normal peripheral blood and bone marrow samples and in acute myeloblastic (AML) and lymphoblastic (ALL) leukemia cases.
  • In samples derived from patients with AML M4 and M5, FXIII-A sensitively identified blast cells.
  • These data provide evidence that FXIII-A is a sufficiently sensitive marker in differentiating myeloblasts and monoblasts and is suitable for identifying leukemia-associated phenotypes in ALL.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Factor XIII / chemistry. Factor XIII / physiology. Leukemia / blood. Leukemia / diagnosis
  • [MeSH-minor] Acute Disease. Animals. Blood Platelets / chemistry. Blood Platelets / metabolism. Blood Platelets / pathology. Flow Cytometry / methods. Humans. Monocytes / chemistry. Monocytes / metabolism. Monocytes / pathology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 International Society for Analytical Cytology.
  • (PMID = 18000871.001).
  • [ISSN] 1552-4930
  • [Journal-full-title] Cytometry. Part A : the journal of the International Society for Analytical Cytology
  • [ISO-abbreviation] Cytometry A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9013-56-3 / Factor XIII
  • [Number-of-references] 56
  •  go-up   go-down


43. Jo A, Tsukimoto I, Ishii E, Asou N, Mitani S, Shimada A, Igarashi T, Hayashi Y, Ichikawa H: Age-associated difference in gene expression of paediatric acute myelomonocytic lineage leukaemia (FAB M4 and M5 subtypes) and its correlation with prognosis. Br J Haematol; 2009 Mar;144(6):917-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-associated difference in gene expression of paediatric acute myelomonocytic lineage leukaemia (FAB M4 and M5 subtypes) and its correlation with prognosis.
  • Acute myeloid leukaemia, French-American-British M4 and M5 subtypes (AML-M4/M5) is frequently associated with MLL gene rearrangement and its incidence is relatively high among infants.
  • Clinically, paediatric AML-M4/M5 has been considered as an intermediate or undefined prognostic group.
  • In this study, we analysed gene expression of 40 paediatric AML-M4/M5 patients excluding inv(16) and t(8;21) patients, and found striking differences among the patients in an age-associated manner.
  • These results suggest that age is an important factor contributing to the biology of AML-M4/M5 and the sub-grouping procedures developed in this study could be a powerful tool to identify unfavourable risk patients within paediatric AML-M4/M5.
  • [MeSH-major] Gene Expression Profiling. Gene Rearrangement. Leukemia, Myelomonocytic, Acute / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19120366.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  •  go-up   go-down


44. Monreal MB, Pardo ML, Pavlovsky MA, Fernandez I, Corrado CS, Giere I, Sapia S, Pavlovsky S: Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia. Cytometry B Clin Cytom; 2006 Mar;70(2):63-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We analyzed the expression of CD38 and HLA-DR on CD34+ cells by flow cytometry in 36 patients with MDS, as well as in healthy donors (n = 12) and patients with other hematological disorders: non-Hodgkin lymphomas and multiple myeloma, both in complete remission (CR) (n = 32); acute lymphoblastic leukemia in CR (n = 17); de novo acute myeloblastic leukemia (AML) at diagnosis (n = 22) and in CR (n = 37); and AML secondary to MDS at diagnosis (n = 19).
  • RESULTS: Compared to normal BM, the fraction of immature HPC, characterized as CD34+bright, intermediate FSC/SSC, and CD38dim, was significantly increased in high risk MDS and secondary AML, but not in low risk MDS, (P < or = 0.001, P = 0.03, and P = 0.7).
  • De novo AML showed decreased immature HPC.
  • High numbers of immature HPC correlated with higher IPSS risk groups (P = 0.05) and showed significant impact on disease progression (P = 0.03).
  • Increased immature HPC in high risk MDS and secondary AML may reflect blocked differentiation of CD34+ cells in these diseases.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Disease Progression. Female. Flow Cytometry. HLA-DR Antigens / immunology. Humans. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / immunology. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / immunology. Male. Middle Aged. Multiple Myeloma / diagnosis. Multiple Myeloma / immunology. Observer Variation. Phenotype. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Prognosis. Reproducibility of Results. Risk Factors

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 International Society for Analytical Cytology.
  • (PMID = 16470534.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / HLA-DR Antigens; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


45. Tsavaris N, Kopterides P, Kosmas C, Siakantaris M, Patsouris E, Pangalis G: Spontaneous remission of acute myeloid leukemia associated with GnRH agonist treatment. Leuk Lymphoma; 2006 Mar;47(3):557-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of acute myeloid leukemia associated with GnRH agonist treatment.
  • Spontaneous remission of acute myeloid leukemia (AML) in adults is a rare but well documented phenomenon.
  • This study reports on a 64-year-old male patient with acute myelogenous leukemia (AML-M4, according to the French-American-British classification) that was developed on a background of chronic myelomonocytic leukemia (CMML) and then underwent remission after treatment with the gonadotropin-releasing hormone agonist (GnRH agonist) triptorelin for presumed prostate cancer.
  • To the author' knowledge, this is the first report of remission in an AML-M4 case associated with hormone manipulation.
  • [MeSH-major] Gonadotropin-Releasing Hormone / agonists. Leukemia, Myelomonocytic, Acute / drug therapy. Leukemia, Myelomonocytic, Acute / pathology. Leukemia, Myelomonocytic, Chronic / drug therapy. Triptorelin Pamoate / therapeutic use

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396781.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone; 57773-63-4 / Triptorelin Pamoate
  •  go-up   go-down


46. Takahashi W, Arai Y, Tadokoro J, Takeuchi K, Yamagata T, Mitani K: [Disappearance of a Philadelphia chromosome-positive clone and appearance of a -negative clone following treatment with imatinib mesylate in acute myelomonocytic leukemia]. Rinsho Ketsueki; 2006 Feb;47(2):111-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Disappearance of a Philadelphia chromosome-positive clone and appearance of a -negative clone following treatment with imatinib mesylate in acute myelomonocytic leukemia].
  • A 63-year-old female was diagnosed as having Philadelphia chromosome-positive acute myelomonocytic leukemia in June 2002.
  • The patient received monotherapy with imatinib mesylate or combination therapy with DCM and idarubicin/cytarabine, both of which failed in attaining disease remission.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative. Leukemia, Myelomonocytic, Acute / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use

  • Genetic Alliance. consumer health - Acute Myelomonocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16529013.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


47. Italia KY, Colah R, Mohanty D: Evaluation of F cells in sickle cell disorders by flow cytometry -- comparison with the Kleihauer-Betke's slide method. Int J Lab Hematol; 2007 Dec;29(6):409-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adult F cell numbers are raised in inherited haemoglobin disorders, such as beta-thalassaemia and sickle cell anaemia, hereditary persistence of foetal haemoglobin, and some acquired conditions, such as juvenile myelomonocytic leukaemia, during acute erythropoietic stress and pregnancy.
  • [MeSH-minor] Adult. Erythropoiesis. Female. Fetomaternal Transfusion / blood. Fetomaternal Transfusion / pathology. Humans. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / pathology. Male. Pregnancy. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Sickle Cell Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988294.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9034-63-3 / Fetal Hemoglobin
  •  go-up   go-down


48. Ali R, Ozkalemkas F, Ozkocaman V, Ozcelik T, Akalin H, Ozkan A, Altundal Y, Tunali A: Hydatid disease in acute leukemia: effect of anticancer treatment on echinococcosis. Microbes Infect; 2005 Jul;7(9-10):1073-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydatid disease in acute leukemia: effect of anticancer treatment on echinococcosis.
  • Echinococcosis, also known as hydatid disease or hydatidosis, is a zoonotic illness caused by the larval form of Echinococcus spp.
  • We treated and followed approximately 1200 patients with different hematologic neoplastic diseases between 1985 and 2003, and only one of these individuals had concomitant acute leukemia and liver hydatidosis.
  • This report describes the case of a 19-year-old man who had both primary refractoriness of acute leukemia (AML-M4) and liver hydatidosis.
  • The patient underwent 3 months of treatment with agents that targeted the leukemia (daunorubicin, idarubicin, cytarabine, fludarabine) and its complications (amphotericin B, amphotericin B lipid complex, liposomal amphotericin B).

  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15996888.001).
  • [ISSN] 1286-4579
  • [Journal-full-title] Microbes and infection
  • [ISO-abbreviation] Microbes Infect.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


49. Hisasue M, Nishimura T, Neo S, Nagashima N, Ishikawa T, Tsuchiya R, Yamada T: A dog with acute myelomonocytic leukemia. J Vet Med Sci; 2008 Jun;70(6):619-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dog with acute myelomonocytic leukemia.
  • The dog was diagnosed with myelomonocytic leukemia (M4) because the blast cells were demonstrated by cytochemical staining to be both myeloid and monocytic cells.
  • This case is the first report of M4 in Japan.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628605.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 12001-79-5 / Vitamin K; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


50. Matsuo Y, Drexler HG, Harashima A, Okochi A, Kojima K, Asakura S, Tanimoto M, Orita K: Acute myeloid leukemia cell lines MOLM-17 and MOLM-18 derived from patient with advanced myelodysplastic syndromes. Leuk Res; 2005 Jun;29(6):701-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia cell lines MOLM-17 and MOLM-18 derived from patient with advanced myelodysplastic syndromes.
  • The two acute myelomonocytic leukemia sister cell lines MOLM-17 and MOLM-18 and the Epstein-Barr-virus positive non-malignant B-lymphoblastoid cell lines (B-LCLs) B422 and B423 were established from the bone marrow sample of a 60-year-old Japanese male in the advanced leukemic phase of refractory anemia with excess of blasts, a subtype of myelodysplastic syndromes (MDS).
  • MOLM-17 and B422 were established at eight months after the initial diagnosis, while MOLM-18 and B423 were derived from a sample one month later.
  • Immunophenotyping of the first leukemia sample revealed a mixed lineage leukemia immunophenotype with positivity for terminal deoxynucleotidyl transferase (TdT), CD13 and CD19; the second sample revealed solely myeloid characteristics with positivity for CD13, CD41 and CD61, whereas TdT was negative.
  • MOLM-17/-18 showed immunomarker profiles typical of the myelomonocytic lineage.
  • [MeSH-major] Cell Line, Tumor / pathology. Leukemia, Myeloid, Acute / pathology. Myelodysplastic Syndromes / complications. Myelodysplastic Syndromes / pathology


51. Naithani R, Mahapatra M: Parotid involvement in acute myelomonocytic leukemia. Indian J Pediatr; 2007 Oct;74(10):965-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid involvement in acute myelomonocytic leukemia.
  • [MeSH-major] Leukemia, Myelomonocytic, Acute / pathology. Leukemic Infiltration / pathology. Parotid Gland / pathology
  • [MeSH-minor] Biopsy, Needle. Bone Marrow / pathology. Child. Diagnosis, Differential. Facial Paralysis / pathology. Female. Humans

  • Genetic Alliance. consumer health - Acute Myelomonocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Indian J Pediatr. 2009 Apr;76(4):438-9 [19412591.001]
  • (PMID = 17978464.001).
  • [ISSN] 0973-7693
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  •  go-up   go-down


52. Inukai T, Zhang X, Goto M, Hirose K, Uno K, Akahane K, Nemoto A, Goi K, Sato H, Takahashi K, Honna H, Kagami K, Nakamoto K, Yagita H, Okumura K, Koyama-Okazaki T, Nakazawa S, Sugita K: Resistance of infant leukemia with MLL rearrangement to tumor necrosis factor-related apoptosis-inducing ligand: a possible mechanism for poor sensitivity to antitumor immunity. Leukemia; 2006 Dec;20(12):2119-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance of infant leukemia with MLL rearrangement to tumor necrosis factor-related apoptosis-inducing ligand: a possible mechanism for poor sensitivity to antitumor immunity.
  • Immune escape mechanisms also contribute to the failure of graft-versus-leukemia (GVL) effect after allogeneic hematopoietic stem cell transplantation (allo-SCT).
  • Infant leukemias with mixed-lineage leukemia (MLL) rearrangement have a remarkably short latency, and GVL effect after allo-SCT has not been clearly evidenced in these leukemias.
  • We investigated the in vitro sensitivity of MLL-rearranged acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML) cells to TRAIL- and FasL-mediated cytotoxicity.
  • Most of cell lines and primary leukemia cells were highly resistant to TRAIL primarily owing to low cell-surface expression of death receptors in ALL and simultaneous expression of decoy receptors in AML.
  • Nearly half of cell lines and majority of primary leukemia cells showed low sensitivity to FasL.
  • These results suggest that resistance to death-inducing ligands, particularly to TRAIL, could be one of the mechanisms for a rapid clonal expansion and a poor sensitivity to the GVL effect in infant leukemias with MLL rearrangement.
  • [MeSH-major] Gene Rearrangement. Leukemia / immunology. Myeloid-Lymphoid Leukemia Protein / genetics. TNF-Related Apoptosis-Inducing Ligand / pharmacology. Tumor Escape
  • [MeSH-minor] Drug Resistance, Neoplasm. Graft vs Leukemia Effect. Histone-Lysine N-Methyltransferase. Humans. Infant. Infant, Newborn. NF-kappa B / antagonists & inhibitors. NF-kappa B / metabolism. Receptors, TNF-Related Apoptosis-Inducing Ligand / analysis

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17066095.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / NF-kappa B; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


53. Karam A, Eveillard JR, Ianoto JC, Quinio D, Le Flohic AM, Le Roy JP, Misery L, Berthou C: [Disseminated cutaneous and visceral fusariosis in an aplastic patient: an unusual digestive entry]. Ann Dermatol Venereol; 2005 Mar;132(3):255-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of cutaneous and systemic fusariosis due to Fusarium moniliforme in a patient with acute lymphoblastic leukemia.
  • CASE-REPORT: A 20 year-old male student was suffering from acute type 6 myeloblastic leukemia.
  • Treatment with voriconazole in association with transfusions of leukocytes led to clinical and microbiological cure.
  • DISCUSSION: In our case report, the clinical pattern starting with digestive symptoms suggested dissemination from a digestive site, which is very unusual in Europe.
  • [MeSH-major] Fusarium / pathogenicity. Mycoses / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. AMSACRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15924050.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; 00DPD30SOY / Amsacrine; 04079A1RDZ / Cytarabine; JFU09I87TR / Voriconazole
  •  go-up   go-down


54. Elouennass M, Doghmi K, Fagot T, Soler C, Mac Nab C, Foissaud V, De Revel T, Hervé V: [Hepatosplenic and kidneys candidasis complicating an acute myeloblastic leukemia. A case treated with voriconazole and caspofungin]. Ann Biol Clin (Paris); 2005 Jul-Aug;63(4):423-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatosplenic and kidneys candidasis complicating an acute myeloblastic leukemia. A case treated with voriconazole and caspofungin].
  • We report the observation of hepato-splenic and kidneys candidiasis complicating the chemotherapy of a myeloblastic leukemia (LAM5b).
  • [MeSH-major] Antifungal Agents / therapeutic use. Candidiasis / drug therapy. Kidney Diseases / microbiology. Leukemia, Myeloid, Acute / microbiology. Liver Diseases / microbiology. Peptides, Cyclic / therapeutic use. Pyrimidines / therapeutic use. Splenic Diseases / microbiology. Triazoles / therapeutic use


55. Wang C, Chen Z, Li Z, Cen J: The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells. Leuk Res; 2010 Aug;34(8):1083-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells.
  • The frequency of extramedullary infiltration (EMI) in acute myeloblastic leukemia (AML) is reported up to 40% and most prevalent in myelo-monoblastic and monoblastic subtypes of AML (M4 and M5 according to FAB classification).
  • To explore mechanism underlying EMI, we analyzed SHI-1 cells, a highly invasive human acute monocytic leukemia cell line, and found their strong expression of matrix metalloproteinase 2 (MMP-2), membrane type 1 MMP (MT1-MMP) and tissue inhibitor of metalloproteinase 2 (TIMP-2).
  • SHI-1 cells showed higher invasive ability to traverse reconstituted basement membranes (Matrigel) and stronger activation of proMMP-2 than other leukemia cell line such as NB4, K562, U937 and THP-1 cells.
  • Our study indicated that increasing TIMP-2 in AML patients with EMI may potentially cause adverse effects, particularly in patients containing high levels of MMP-2 and MT1-MMP.
  • [MeSH-major] Leukemia, Monocytic, Acute / metabolism. Leukemia, Monocytic, Acute / pathology. Matrix Metalloproteinase 14 / metabolism. Matrix Metalloproteinase 2 / metabolism. Tissue Inhibitor of Metalloproteinase-2 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20138666.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Laminin; 0 / Matrix Metalloproteinase Inhibitors; 0 / Proteoglycans; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 119978-18-6 / matrigel; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; 9007-34-5 / Collagen; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.80 / MMP14 protein, human; EC 3.4.24.80 / Matrix Metalloproteinase 14
  •  go-up   go-down


56. Jackowska T, Steczowicz M, Pawelec K, Pacholska J: [Congenital leukaemia and transient myeloproliferative disorder: diagnostic difficulties--case reports]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):595-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Congenital leukaemia and transient myeloproliferative disorder: diagnostic difficulties--case reports].
  • Congenital leukaemia occurs in only 0.8% of all cases of leukaemia in children.
  • Despite great progress in the treatment of childhood leukaemia, prognosis is still poor.
  • This type of leukaemia must be distinguished from leukaemic reactions and transient myeloproliferative disorder.
  • Transient myeloproliferative disorder is a rare condition in the neonatal period, connected with trisomy or other abnormalities of chromosome 21.
  • We present two cases: congenital leukaemia and transient myeloproliferative disorder.
  • The first patient was a boy in whom congenital myelomonoblastic leukaemia (M4 in FAB classification) was diagnosed at age of 6 weeks.
  • He was treated according to BFM-96 for acute myeloblasts leukaemia protocol, but there was no remission and he died of progressive congenital leukaemia after 4 months.
  • These cases confirm the difficulties in differentiation between congenital leukaemia and transient myeloproliferative disorder presented in literature.
  • In spite of the same haematological symptoms the only difference may be detection of nonhematopoietic tissue infiltration (skin and central nervous system) commonly occurring in congenital leukaemia or the presence of trisomy and other abnormalities of chromosome 21 in transient myeloproliferative disorder.
  • [MeSH-major] Leukemia, Lymphoid / congenital. Leukemia, Lymphoid / diagnosis. Leukemia, Myeloid, Acute / congenital. Leukemia, Myeloid, Acute / diagnosis. Myeloproliferative Disorders / congenital. Myeloproliferative Disorders / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Down Syndrome / complications. Down Syndrome / diagnosis. Fatal Outcome. Female. Humans. Infant, Newborn. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317890.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


57. Akimkin VG, Ledin EV, Skvortsov SV, Rukavitsyn OA: [Incidence of hepatitis B virus infection in patients with blood disease]. Ter Arkh; 2007;79(11):28-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidence of hepatitis B virus infection in patients with blood disease].
  • AIM: To define incidence of HBV infection in patients with blood diseases caused by blood components transfusion; correlation between infection rate and blood disease nosological entity, intensity of hemoreplacement therapy, time of hepatitis B incubation period in patients with hematological malignancies after the diagnosis and initiation of polychemotherapy (PCT).
  • MATERIAL AND METHODS: In 2000-2007 a prospective clinicoepidemiological trial was made to detect markers of HBV infection among 303 patients 15 to 76 years of age treated in the department of acute leukemia chemotherapy of N.N.
  • Burdenko Military Hospital for acute lymphoid and myeloblastic leukemia, chronic myeloid leukemia in a blastic crisis, myelodysplastic syndrome in blast transformation, lymphoproliferative diseases with bone marrow affection.
  • Among the infected patients there were 16 (53.4%) patients with different variants of acute myeloblastic leukemia, 12 (40.0%) with different immunophenotypes of acute lymphoblastic leukemia, 1 (3.3%) patient with acute biphenotypical leukemia and 1 (3.3%) with lymphoma/leukemia.
  • Most of the patients - 23 (74%) of 30 - were infected with HBV within the first year after hematological diagnosis and PCT induction course.
  • [MeSH-major] Hepatitis B / epidemiology. Leukemia, Myeloid, Acute / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219969.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Biomarkers
  •  go-up   go-down


58. Wojcik I, Szybka M, Golanska E, Rieske P, Blonski JZ, Robak T, Bartkowiak J: Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias. Neoplasma; 2005;52(4):318-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias.
  • Abnormalities of the P53 network have been implicated in the pathogenesis of acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML).
  • The purpose of this study was to define P53 gene mutations, to detect MDM2 gene amplification and to estimate mRNA expression of P53, MDM2, BCL2 and BAX genes in patients with ALL and AML.
  • Twenty-five patients with ALL and 65 patients with AML, both recently diagnosed, were included into this study.
  • Mutation of the P53 gene was found in one patient of the 25 with ALL and in five patients of the 65 with AML.
  • One mutation in intronic sequence in ALL and four missense mutations and one silent nucleotide substitution in AML were identified.
  • Amplification of MDM2 gene was detected by multiplex-PCR analysis in only one sample from patient with ALL, but was not observed in any case of AML.
  • To gain further insight into the role of P53 network in the evolution of acute leukemias, the P53, MDM2, BCL2 and BAX mRNAexpressions in portion samples from patients with ALL and AML were analyzed using multiplex RT-PCR.
  • A high frequency of BCL2 mRNA overexpression and a relatively low frequency of BAX mRNA overexpression detected in both analyzed leukemias in this study, indicate that altered transcription of these genes may be involved in leukemogenesis.
  • [MeSH-major] Gene Amplification. Gene Expression Profiling. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16059649.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / bcl-2-Associated X Protein; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


59. Pulte D, Gondos A, Brenner H: Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981-2005. Cancer; 2009 Nov 1;115(21):4973-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981-2005.
  • METHODS: : Period analysis was used to calculate 5- and 10-year relative survival for adolescents and young adults diagnosed with Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), acute myeloblastic leukemia (AML), and chronic myelocytic leukemia (CML) for 5 5-year periods from 1981-1985 to 2001-2005, using data from the Surveillance, Epidemiology, and End Results database.
  • Increases in 10-year relative survival between 1981-1985 and 2001-2005 were as follows: HL, from 80.4% to 93.4%; NHL, from 55.6% to 76.2%; ALL, from 30.5% to 52.1%; AML, from 15.2% to 45.1%; CML, from 0 to 74.5% (P < .001 in all cases).
  • However, although survival improved steadily throughout the period examined for the lymphomas and CML, survival was stable during the late 1990s and early 21st century for the acute leukemias.
  • However, with the exception of HL, survival rates have not reached the levels observed for children diagnosed with these malignancies, and survival expectations for patients with acute leukemia have stabilized at relatively low levels.
  • [MeSH-minor] Adolescent. Hodgkin Disease / mortality. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality. Leukemia, Myeloid, Acute / mortality. Lymphoma, Non-Hodgkin / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Survival Rate. Time Factors. United States / epidemiology. Young Adult

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19705347.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Koh G, Yamane T, Aoyama Y, Sakamoto C, Nakamae H, Hasegawa T, Terada Y, Hino M: [Acute myelomonocytic leukemia complicated with multiple lower intestinal ulcers induced by nonsteroidal anti-inflammatory drugs]. Gan To Kagaku Ryoho; 2005 Jan;32(1):111-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute myelomonocytic leukemia complicated with multiple lower intestinal ulcers induced by nonsteroidal anti-inflammatory drugs].
  • We report an 18-year-old woman with acute myelomonocytic leukemia, who developed massive lower intestinal bleeding following induction chemotherapy.
  • Colonoscopy revealed multiple circular ulcers but no infectious colitis or infiltration of leukemia.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Colonic Diseases / chemically induced. Leukemia, Myelomonocytic, Acute / complications. Peptic Ulcer Hemorrhage / chemically induced

  • Genetic Alliance. consumer health - Acute Myelomonocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15675595.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


61. Reiterer G, Yen A: Platelet-derived growth factor receptor regulates myeloid and monocytic differentiation of HL-60 cells. Cancer Res; 2007 Aug 15;67(16):7765-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelet-derived growth factor receptor regulates myeloid and monocytic differentiation of HL-60 cells.
  • Here, we show that the platelet-derived growth factor receptor (PDGFR) regulates myeloid and monocytic differentiation of HL-60 myeloblastic leukemia cells in response to retinoic acid (RA) and vitamin D3 (D3), respectively.
  • In addition, we found calcium levels to be decreased by RA and D3 but increased when AG1296 was given in addition to RA or D3, suggesting that calcium levels decrease during myeloid or monocytic differentiation, and elevated calcium levels can disturb the expression of certain differentiation markers.
  • [MeSH-major] Monocytes / pathology. Myeloid Cells / pathology. Receptors, Platelet-Derived Growth Factor / metabolism

  • COS Scholar Universe. author profiles.
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. CHOLECALCIFEROL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17699781.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA33505; United States / NIDDK NIH HHS / DK / DK072105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD11b; 0 / Antigens, CD14; 0 / CEACAM6 protein, human; 0 / Cell Adhesion Molecules; 0 / Fc(alpha) receptor; 0 / GPI-Linked Proteins; 0 / ITGAM protein, human; 0 / Membrane Glycoproteins; 0 / Receptors, Fc; 0 / Tyrphostins; 0 / Ubiquitin; 146535-11-7 / 6,7-dimethoxy-3-phenylquinoxaline; 1C6V77QF41 / Cholecalciferol; 5688UTC01R / Tretinoin; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human; SY7Q814VUP / Calcium
  •  go-up   go-down


62. Emerenciano M, Agudelo Arias DP, Coser VM, de Brito GD, Macedo Silva ML, Pombo-de-Oliveira MS, Brazilian Collaborative Study Group of Infant Acute Leukemia: Molecular cytogenetic findings of acute leukemia included in the Brazilian Collaborative Study Group of Infant acute leukemia. Pediatr Blood Cancer; 2006 Oct 15;47(5):549-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic findings of acute leukemia included in the Brazilian Collaborative Study Group of Infant acute leukemia.
  • BACKGROUND: Chromosome abnormalities often occur prenatally in childhood leukemia, characterizing an early event in leukemogenesis.
  • We describe the molecular cytogenetic findings of 207 infant acute leukemia (IAL) cases included in the Brazilian Collaborative Study Group of Infant acute leukemia.
  • PROCEDURE: The diagnosis of Acute Lymphoblastic leukemia (ALL) or acute myeloblastic leukemia (AML) was made according to morphology and immunophenotyping classification, followed by conventional karyotyping.
  • RESULTS: The characteristics of children with IAL were as follows: 115 boys and 92 girls, age range 0-23 months, mean age 12 months, 145 ALL, and 62 AML.
  • [MeSH-major] Cytogenetic Analysis / methods. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16261608.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Park IJ, Park JE, Kim HJ, Jung HJ, Lee WG, Cho SR: Acute myeloid leukemia with t(16;21)(q24;q22) and eosinophilia: case report and review of the literature. Cancer Genet Cytogenet; 2010 Jan 1;196(1):105-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia with t(16;21)(q24;q22) and eosinophilia: case report and review of the literature.
  • The t(16;21)(q24;q22), a rare chromosomal translocation involving chromosome 21 in de novo and therapy-related acute myeloid leukemia (AML), produces a RUNX1-CBFA2T3 fusion gene (previously AML1-MTG16) fusion gene.
  • The translocation has been reported in 20 patients with AML, with eosinophilia present in 3 cases.
  • Here we report a pediatric case of t(16;21)(q24;q22) in de novo AML with eosinophilia and suggest that eosinophilia is a hematologic characteristic of at least a subpopulation of AML with t(16;21)(q24;q22).
  • A 4-year-old Korean girl was admitted with complaints of pale appearance and dizziness, and was diagnosed with acute myelomonocytic leukemia.
  • [MeSH-minor] Child, Preschool. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Leukemia, Myeloid, Acute. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19963144.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


64. Sakai R, Fujimaki K, Yamazaki E, Sakamoto H, Kanamori H, Miura I, Ishigatsubo Y: Acute myelomonocytic leukemia with dysplastic bone marrow eosinophils showing t(5;17)(q13;q11) and a secondary chromosomal aberration, inv(16)(p13q22). Int J Hematol; 2006 Dec;84(5):417-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelomonocytic leukemia with dysplastic bone marrow eosinophils showing t(5;17)(q13;q11) and a secondary chromosomal aberration, inv(16)(p13q22).
  • inv(16)(p13q22) is associated with de novo acute myelomonocytic leukemia with dysplastic bone marrow eosinophils (AMML Eo), which has a relatively favorable clinical course with a longer remission duration and better survival prospects.
  • On the other hand, t(5; 17)(q13;q11), although relatively rare, has been reported to be a component of complex chromosomal abnormalities in myelodysplastic syndromes and secondary acute myeloid leukemia (AML).
  • We treated a 29-year-old woman with the first reported case of de novo AMML Eo with inv(16)(p13q22) in addition to t(5; 17)(q13;q11).
  • Although she attained complete remission (CR) immediately after induction therapy, the disease recurred 1 year after the completion of consolidation therapies.
  • In general, certain secondary chromosomal abnormalities are associated with the phenotype of the disease, which retains its essential biologic characteristics established by the primary abnormality.
  • Accordingly, the primary nature of the leukemic cells in this case differs from the findings for core-binding factor AML with inv(16)(p13q22).
  • We believe this report is the first of de novo AMML Eo with t(5; 17)(q13;q11) showing as a secondary chromosomal aberration with inv(16)(p13q22).
  • [MeSH-major] Bone Marrow Cells / pathology. Chromosome Inversion. Chromosomes, Human / genetics. Eosinophils / pathology. Leukemia, Myelomonocytic, Acute. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Myelomonocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2005 Apr 14;24(16):2625-34 [15782145.001]
  • [Cites] Oncogene. 1990 Oct;5(10):1557-63 [1701231.001]
  • [Cites] Blood. 1993 Dec 1;82(11):3424-9 [8241509.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5705-17 [16110030.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Mar;59(1):35-8 [1555189.001]
  • [Cites] Leuk Res. 2007 Jan;31(1):39-47 [16687173.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Jul 15;61(2):197-200 [1638503.001]
  • [Cites] N Engl J Med. 1983 Sep 15;309(11):630-6 [6577285.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Leukemia. 1992 May;6(5):381-4 [1593903.001]
  • [Cites] Blood. 1998 Feb 1;91(3):1008-15 [9446663.001]
  • [Cites] Blood. 1986 Feb;67(2):270-4 [3455826.001]
  • [Cites] Leukemia. 1994 Jun;8(6):953-62 [8207990.001]
  • [Cites] Leuk Lymphoma. 1998 Sep;31(1-2):231-6 [9720733.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2726-34 [16284985.001]
  • [Cites] Cancer Genet Cytogenet. 1989 Oct 1;42(1):43-50 [2790745.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2138-43 [10706886.001]
  • (PMID = 17189222.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


65. Kuwata T, Nakamura T: BCL11A is a SUMOylated protein and recruits SUMO-conjugation enzymes in its nuclear body. Genes Cells; 2008 Sep;13(9):931-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies show that BCL11A is involved in acute myelomonocytic leukemia and chronic lymphoid leukemia in mouse and human, respectively.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. L-Lysine .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681895.001).
  • [ISSN] 1365-2443
  • [Journal-full-title] Genes to cells : devoted to molecular & cellular mechanisms
  • [ISO-abbreviation] Genes Cells
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCL11A protein, human; 0 / Carrier Proteins; 0 / Nuclear Proteins; 0 / Recombinant Proteins; 0 / SUMO-1 Protein; 0 / Small Ubiquitin-Related Modifier Proteins; 147336-22-9 / Green Fluorescent Proteins; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.- / SENP2 protein, human; EC 6.3.2.19 / Ubiquitin-Conjugating Enzymes; EC 6.3.2.19 / ubiquitin-conjugating enzyme UBC9; K3Z4F929H6 / Lysine
  •  go-up   go-down


66. Tasca S, Furlanello T, Caldin M: High serum and urine lysozyme levels in a dog with acute myeloid leukemia. J Vet Diagn Invest; 2010 Jan;22(1):111-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High serum and urine lysozyme levels in a dog with acute myeloid leukemia.
  • A 2-year-old, female German Shepherd Dog with facial nerve paralysis was diagnosed with acute myelomonocytic leukemia based on clinical, cytologic, and immunologic findings.
  • A diagnosis of tubular proteinuria was made, and a chemical evaluation of LZM in serum and urine samples was performed using a turbidimetric assay.
  • [MeSH-major] Dog Diseases / blood. Leukemia, Myeloid, Acute / veterinary. Muramidase / blood

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20093697.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.1.17 / Muramidase
  •  go-up   go-down


67. Patnaik MM, Gangat N, Knudson RA, Keefe JG, Hanson CA, Pardanani A, Ketterling RP, Tefferi A: Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. Am J Hematol; 2010 Apr;85(4):238-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FISH analysis was performed in 13 patients (12 had myeloid neoplasms) and revealed abnormalities of MYST3 (n = 4) or FGFR1 (n = 4) in eight patients.
  • MYST3 abnormalities were associated with acute myeloid leukemia (AML), M4 in three and M6 in one.
  • Three of the four FGFR1-rearranged cases were associated with myeloproliferative neoplasms but none, including the two with sole 8p11.2, displayed the typical phenotype for stem cell leukemia/lymphoma (SCLL) and only one had eosinophilia; the fourth case had AML-M4.
  • [MeSH-major] Chromosomes, Human, Pair 8 / genetics. Hematologic Neoplasms / genetics. Histone Acetyltransferases / genetics. In Situ Hybridization, Fluorescence / methods. Myeloproliferative Disorders / genetics. Oncogene Fusion. Receptor, Fibroblast Growth Factor, Type 1 / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Aged. Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology. Cohort Studies. Eosinophilia / genetics. Female. Genetic Predisposition to Disease. Genetic Testing. Humans. Karyotyping. Leukemia, Myeloid, Acute / genetics. Male. Middle Aged. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20143402.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / KAT6A protein, human; EC 2.7.10.1 / FGFR1 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1
  •  go-up   go-down


68. Karabacak BH, Erbey F, Bayram I, Yilmaz S, Acipayam C, Kilinç Y, Tanyeli A: Fms-like tyrosine kinase 3 mutations in childhood acute leukemias and their association with prognosis. Asian Pac J Cancer Prev; 2010;11(4):923-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fms-like tyrosine kinase 3 mutations in childhood acute leukemias and their association with prognosis.
  • OBJECTIVE: In this study, the presence of FLT3 mutations in childhood acute leukemias patients and their association with prognosis were investigated.
  • MATERIALS AND METHODS: A total of 120 patients, 80 with acute lymphoblastic leukemia (ALL) and 40 with acute myeloblastic leukemia (AML), were included.
  • RESULTS: FLT3/ITD (internal tandem duplication) mutations were found in 6 (7.5%) of the patients with ALL and in 9 (22.5%) of those with AML, whereas no FLT3/TKD (trans kinase domain) mutation was evident in any case.
  • There was no difference between the ALL patients positive and negative for FLT3/ITD with regard to overall survival (OS), event free survival (EFS) and disease free survival (DFS) (p=0.37, p=0.23, p=0.023, respectively).
  • However, in FLT3/ITD positive and negative AML patients, there was a statistically significant difference in OS (p=0.0041), but not EFS and DFS (p=0.09, p=0.095, respectively).
  • CONCLUSION: We found that FLT3/ITD positivity increased with age and that it was associated with decrease in OS in AML patients, providing further evidence that it is an independent factor negatively influencing prognosis.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / mortality. Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Disease-Free Survival. Humans. Infant. Kaplan-Meier Estimate. Male. Prognosis. Recurrence

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21133602.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


69. Konuma T, Tomonari A, Takahashi S, Ooi J, Tsukada N, Yamada T, Sato H, Nagayama H, Iseki T, Tojo A, Asano S: Early-onset thyrotoxicosis after unrelated cord blood transplantation for acute myelogenous leukemia. Int J Hematol; 2006 May;83(4):348-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-onset thyrotoxicosis after unrelated cord blood transplantation for acute myelogenous leukemia.
  • Patient 1 is a 32-year-old woman with acute myelogenous leukemia (AML)-M5a who underwent CBT.
  • Patient 2 is a 42-year-old man with AML-M4 who underwent CBT.
  • [MeSH-major] Autoimmune Diseases / blood. Cord Blood Stem Cell Transplantation. Leukemia, Myeloid, Acute. Thyrotoxicosis / blood

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1997 Aug;98(2):453-7 [9266950.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jan;74(1):3-5 [1727826.001]
  • [Cites] Transplantation. 2001 Feb 15;71(3):406-11 [11233902.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Nov;89(11):5810-4 [15531546.001]
  • [Cites] Br J Haematol. 1993 Dec;85(4):778-82 [7918043.001]
  • [Cites] Transplantation. 1987 Sep;44(3):463-4 [3307069.001]
  • [Cites] Bone Marrow Transplant. 2000 Dec;26(12):1347-9 [11223977.001]
  • [Cites] Bone Marrow Transplant. 1990 Jul;6(1):49-51 [2390632.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):660-3 [11736951.001]
  • [Cites] Bone Marrow Transplant. 1995 Jan;15(1):71-6 [7742758.001]
  • [Cites] Br J Haematol. 1990 Jan;74(1):118-9 [2310693.001]
  • [Cites] N Engl J Med. 1985 Feb 28;312(9):546-52 [3881675.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):2965-71 [12843128.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3813-20 [15280199.001]
  • [Cites] Blood. 2004 Jan 15;103(2):489-91 [12933570.001]
  • [Cites] Bone Marrow Transplant. 1992 Oct;10(4):397-8 [1422500.001]
  • (PMID = 16757437.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Autoantibodies; 06LU7C9H1V / Triiodothyronine; EC 1.11.1.8 / Iodide Peroxidase; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


70. Cho WH, Choi YJ, Choi BK, Cha SH: Isolated recurrence of intracranial granulocytic sarcoma mimicking a falx meningioma in acute myeloblastic leukemia. J Korean Neurosurg Soc; 2010 May;47(5):385-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated recurrence of intracranial granulocytic sarcoma mimicking a falx meningioma in acute myeloblastic leukemia.
  • Intracranial granulocytic sarcomas are rare tumors, which are composed of immature granulocytic cells.
  • Although it has been well known that these tumors are associated with acute myeloblastic leukemia (AML), they have been almost always related to bone marrow relapse.
  • However, isolated recurrence of granulocytic sarcoma following complete remission from prior AML is extremely rare, especially in the central nervous system.
  • A 44-year-old male presented with isolated recurrence of granulocytic sarcoma mimicking a falx meningioma two years after complete remission by allogenic peripheral blood stem cell transfusion (PBSCT) in the acute myelomonoblastic leukemia (FAB, M4).
  • Pathological findings were compatible with the granulocytic sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1986 Dec 15;58(12):2697-709 [3465429.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Jun;44(6):311-6 [15253547.001]
  • [Cites] AJR Am J Roentgenol. 1984 Apr;142(4):777-8 [6322560.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2107-12 [7512442.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1800-16 [7602369.001]
  • [Cites] Ann Intern Med. 1995 Sep 1;123(5):351-3 [7625623.001]
  • [Cites] Cancer. 1977 Dec;40(6):3030-7 [338140.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Mar-Apr;12(2):259-62 [1902023.001]
  • [Cites] Leuk Lymphoma. 1994 Oct;15(3-4):351-5 [7866286.001]
  • [Cites] Radiology. 1994 Mar;190(3):698-702 [8115614.001]
  • [Cites] Bone Marrow Transplant. 1996 Sep;18(3):663-4 [8879638.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Sep;17(8):1592-4 [8883663.001]
  • [Cites] Leuk Lymphoma. 1996 Mar;21(1-2):153-9 [8907283.001]
  • [Cites] Gastrointest Endosc. 1998 Aug;48(2):190 [9717786.001]
  • [Cites] Clin Neurol Neurosurg. 1998 Sep;100(3):205-8 [9822843.001]
  • [Cites] Jpn J Clin Oncol. 1999 Apr;29(4):214-8 [10340046.001]
  • [Cites] Radiology. 1985 Apr;155(1):167-70 [3856292.001]
  • (PMID = 20539800.001).
  • [ISSN] 1598-7876
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2883061
  • [Keywords] NOTNLM ; Chloroma / Granulocytic sarcoma / Leukemia
  •  go-up   go-down


71. Wonsettler DM, Chang WW, Wenger SL: Extra copy of 20q deletion, acute myelomonocytic leukemia (M4) and Niemann-Pick disease. J Assoc Genet Technol; 2005;31(2):55-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extra copy of 20q deletion, acute myelomonocytic leukemia (M4) and Niemann-Pick disease.
  • A 59-year-old hypertensive white male was diagnosed with acute myelogenous leukemia (AML), M4.
  • The majority of cases with 20q deletion are associated with myeloid disorders; however, an extra copy of the 20q deletion has rarely been reported.
  • Many foamy macrophages with bubbling cytoplasm in the spleen, liver, bone marrow and lymph nodes were suggestive of Niemann-Pick disease, type E.
  • AML has not previously been reported with Niemann-Pick disease.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16027483.001).
  • [ISSN] 1523-7834
  • [Journal-full-title] Journal of the Association of Genetic Technologists
  • [ISO-abbreviation] J Assoc Genet Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Aoki T, Miyamoto T, Yoshida S, Yamamoto A, Yamauchi T, Yoshimoto G, Mori Y, Kamezaki K, Iwasaki H, Takenaka K, Harada N, Nagafuji K, Teshima T, Akashi K: Additional acquisition of t(1;21)(p32;q22) in a patient relapsing with acute myelogenous leukemia with NUP98-HOXA9. Int J Hematol; 2008 Dec;88(5):571-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional acquisition of t(1;21)(p32;q22) in a patient relapsing with acute myelogenous leukemia with NUP98-HOXA9.
  • We report a 29-year-old Japanese male with acute myelogenous leukemia (AML)-M4 with a cryptic t(7;11)(p15;p15), in which a chimeric NUP98-HOXA9 fusion was detected by polymerase chain reaction analysis and a chromosomal analysis showed 46,XY.
  • This is the first reported case with AML who had a cryptic t(7;11)(p15;p15), and additionally acquired t(1;21)(p32;q22) at relapse.
  • [MeSH-major] Chromosomes, Human / genetics. Core Binding Factor Alpha 2 Subunit / genetics. Homeodomain Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy. Nuclear Pore Complex Proteins / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1992 Mar;6(3):232 [1564964.001]
  • [Cites] Int J Hematol. 2006 Aug;84(2):136-42 [16926135.001]
  • [Cites] Blood. 1998 Jul 15;92(2):574-88 [9657758.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Sep;129(2):155-60 [11566347.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(10):821-6 [9404921.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11781-91 [17178874.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):159-67 [8563754.001]
  • [Cites] Blood. 2005 Jan 15;105(2):784-93 [15454493.001]
  • [Cites] Cancer Invest. 2003;21(1):105-36 [12643014.001]
  • [Cites] Curr Opin Hematol. 2005 May;12(3):210-6 [15867577.001]
  • [Cites] Br J Haematol. 1997 Mar;96(4):682-7 [9074407.001]
  • [Cites] Oncogene. 2008 Jun 19;27(27):3765-79 [18264136.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1532-42 [12176867.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jun;1106:114-42 [17442773.001]
  • [Cites] Blood. 2002 Jan 1;99(1):310-8 [11756186.001]
  • [Cites] Am J Hematol. 1994 Sep;47(1):62-4 [8042621.001]
  • [Cites] Haematologica. 2007 Jun;92(6):861-2 [17550866.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):600-4 [10583265.001]
  • [Cites] EMBO J. 2001 Feb 1;20(3):350-61 [11157742.001]
  • [Cites] Leukemia. 2001 Nov;15(11):1689-95 [11681408.001]
  • [Cites] Haematologica. 1997 May-Jun;82(3):364-70 [9234595.001]
  • (PMID = 19005624.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Homeodomain Proteins; 0 / NUP98-HOXA9 fusion protein, human; 0 / Nuclear Pore Complex Proteins; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


73. Douet-Guilbert N, Morel F, Le Bris MJ, Herry A, Morice P, Bourquard P, Banzakour S, Le Calvez G, Marion V, Berthou C, De Braekeleer M: Rearrangement of the MLL gene in acute myeloblastic leukemia: report of two rare translocations. Cancer Genet Cytogenet; 2005 Mar;157(2):169-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rearrangement of the MLL gene in acute myeloblastic leukemia: report of two rare translocations.
  • We report here 2 male adults in whom a diagnosis of acute myelomonoblastic leukemia (FAB M4) and acute monoblastic leukemia (FAB M5) was made.
  • Fourteen and 24 patients, including ours, with acute myeloblastic leukemia associated with a t(1;11)(p32;q23) and a t(11;17)(q23;q21), respectively have been reported in the literature.
  • Several patients with the latter translocation have also been identified to have acute lymphoblastic leukemia (ALL).
  • Although both translocations are preferentially associated with monocytic differentiation, the t(11;17)(q23;q21) is more common in adults and has been reported in many patients with ALL, compared to the t(1;11)(p32;q23).
  • [MeSH-major] Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 17. DNA-Binding Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Proto-Oncogenes / genetics. Transcription Factors / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Histone-Lysine N-Methyltransferase. Humans. Karyotyping. Male. Middle Aged. Myeloid-Lymphoid Leukemia Protein

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721641.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


74. Kappelmayer J, Simon A, Katona E, Szanto A, Nagy L, Kiss A, Kiss C, Muszbek L: Coagulation factor XIII-A. A flow cytometric intracellular marker in the classification of acute myeloid leukemias. Thromb Haemost; 2005 Aug;94(2):454-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coagulation factor XIII-A. A flow cytometric intracellular marker in the classification of acute myeloid leukemias.
  • This study was designed to study the sensitivity and specificity of factor XIII subunit A (FXIII-A) labelling in cultured myeloblastic and monoblastic cell lines and to investigate the intracytoplasmic expression of FXIII-A in de novo acute myeloid leukemia (AML) samples.
  • Myeloblastic and a monoblastic cell lines were cultured and investigated for lineage specific maturation markers and FXIII-A expression.
  • Furthermore, FXIII-A expression was investigated in 12 normal samples (7 bone marrow and 5 peripheral blood), 86 de novo AML samples and 6 chronic myelomonocytic leukemia (CMML) samples.
  • In the monoblastic MonoMac6 cell line the appearance of FXIII-A preceded that of CD14 while it remained negative in the myeloblastic PLB-985 cell line throughout its maturation period.
  • Among the AML samples the average frequency of FXIII-A positive cells in myeloblastic leukemia samples was below 10%, while in M4 and M5AML samples it was above 50% and was significantly higher than the generally used CD14 marker (p < 0.0001).
  • In the AML M4 and M5 cases, FXIII-A proved sensitive for the identification of monoblasts.
  • FXIII-A can be considered as a reliable intracytoplasmic marker for the monocytic and megakaryocytic series and its presence is highly predictive for mono- and megakaryocytic AML and for CMML.
  • [MeSH-major] Factor XIIIa / metabolism. Factor XIIIa / physiology. Flow Cytometry / methods. Leukemia, Myeloid, Acute / metabolism
  • [MeSH-minor] Antibodies, Monoclonal / metabolism. Antigens, CD14 / biosynthesis. Cell Line. Cell Line, Tumor. Cell Lineage. Cells, Cultured. Cytoplasm / metabolism. Granulocytes / cytology. Humans. Leukocytes / metabolism. Megakaryocytes / cytology. Monocytes / cytology. Monocytes / metabolism. Myeloid Cells / cytology. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16113839.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD14; EC 2.3.2.13 / Factor XIIIa
  •  go-up   go-down


75. Rocquain J, Gelsi-Boyer V, Adélaïde J, Murati A, Carbuccia N, Vey N, Birnbaum D, Mozziconacci MJ, Chaffanet M: Alteration of cohesin genes in myeloid diseases. Am J Hematol; 2010 Sep;85(9):717-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration of cohesin genes in myeloid diseases.
  • We have studied by array-comparative genomic hybridization (aCGH) a series of 167 samples including myelodysplastic syndromes, chronic myelomonocytic leukemias, and acute myeloid leukemias.
  • [MeSH-major] Antigens, Nuclear / genetics. Cell Cycle Proteins / genetics. Chromosomal Proteins, Non-Histone / genetics. Gene Deletion. Leukemia, Myeloid / genetics. Myelodysplastic Syndromes / genetics. Nuclear Proteins / genetics. Phosphoproteins / genetics

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20687102.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ASXL1 protein, human; 0 / Antigens, Nuclear; 0 / Cell Cycle Proteins; 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Phosphoproteins; 0 / Proto-Oncogene Proteins; 0 / RAD21 protein, human; 0 / Repressor Proteins; 0 / STAG2 protein, human; 0 / TET2 protein, human; 0 / cohesins
  •  go-up   go-down


76. Shimizu T, Esaki L, Mizuno H, Takeda K: Granulocyte macrophage colony-stimulating factor enhances retinoic acid-induced gene expression. J Leukoc Biol; 2006 Oct;80(4):889-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reported previously that treatment of human myeloblastic leukemia ML-1 cells with all-trans retinoic acid (ATRA) in combination with GM-CSF enhances the granulocytic differentiation, which is induced only slightly by ATRA alone.
  • Further studies of the mechanism underlying this effect may identify better approaches for the treatment of RA-insensitive leukemia.
  • [MeSH-major] Gene Expression / drug effects. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Leukemia, Myeloid, Acute / drug therapy. Oligonucleotide Array Sequence Analysis / methods. Tretinoin / pharmacology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885501.001).
  • [ISSN] 0741-5400
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5688UTC01R / Tretinoin; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


77. Sumi M, Ichikawa N, Nasu K, Shimizu I, Ueki T, Ueno M, Kobayashi H: Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation. Int J Hematol; 2009 Dec;90(5):643-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation.
  • A 56-year-old woman with acute myelomonocytic leukemia underwent myeloablative allogeneic hematopoietic stem cell transplantation (allo-SCT) from a matched unrelated donor in her first complete remission (CR).
  • Veno-occlusive disease (VOD) prophylaxis consisted of low-dose heparin and ursodeoxycholic acid.
  • Graft-versus-host disease (GVHD) prophylaxis comprised tacrolimus and short-term methotrexate.
  • On day 58, she showed grade II acute GVHD, but this resolved spontaneously.
  • Although the standard treatment for acute myeloid leukemia relapse after allo-SCT still remains to be established, GO may be a promising option.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myelomonocytic, Acute / drug therapy. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Acute Myelomonocytic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2002 Jul;30(1):23-8 [12105773.001]
  • [Cites] Leukemia. 2005 Feb;19(2):176-82 [15592433.001]
  • [Cites] Ann Hematol. 2001 Feb;80(2):119-20 [11261323.001]
  • [Cites] Blood. 1990 Feb 1;75(3):555-62 [2297567.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Aug;4(8):491-5 [17657254.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4371-83 [19029455.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1273-4 [17989711.001]
  • [Cites] Int J Hematol. 2009 May;89(4):460-9 [19360457.001]
  • [Cites] Leukemia. 2007 Jan;21(1):66-71 [17051246.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):495-503 [17952130.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1442-52 [16116598.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Leukemia. 2004 Feb;18(2):316-25 [14614514.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2247-8 [12960967.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4207-15 [12010827.001]
  • (PMID = 19904520.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 93NS566KF7 / gemtuzumab
  •  go-up   go-down


78. Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, Kuemmerle-Deschner J, Frühwald MC, Dassmann S, Pham TH, Roth J, Foell D: S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum; 2008 Dec;58(12):3924-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differential diagnosis includes systemic-onset juvenile idiopathic arthritis (JIA), an autoinflammatory syndrome associated with activation of phagocytic cells that, at presentation, is difficult to differentiate from severe systemic infections.
  • METHODS: Serum samples were obtained from 45 healthy control subjects and from 240 patients (60 with systemic-onset JIA, 17 with familial Mediterranean fever [FMF], 18 with neonatal-onset multisystem inflammatory disease [NOMID], 17 with Muckle-Wells syndrome [MWS], 40 with acute lymphoblastic leukemia [ALL], 5 with acute myeloblastic leukemia [AML], and 83 with systemic infections).
  • RESULTS: The mean +/- 95% confidence interval serum levels of S100A12 were as follows: in patients with JIA, 7,190 +/- 2,690 ng/ml; in patients with FMF, 6,720 +/- 4,960 ng/ml; in patients with NOMID, 720 +/- 450 ng/ml; in patients with MWS, 150 +/- 60 ng/ml; in patients with infections, 470 +/- 160 ng/ml; in patients with ALL, 130 +/- 80 ng/ml; in patients with AML, 45 +/- 60 ng/ml; in healthy control subjects, 50 +/- 10 ng/ml.
  • [MeSH-major] Arthritis, Juvenile / blood. Arthritis, Juvenile / diagnosis. Biomarkers / blood. Fever of Unknown Origin / blood. Fever of Unknown Origin / diagnosis. S100 Proteins / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Familial Mediterranean Fever / blood. Familial Mediterranean Fever / diagnosis. Familial Mediterranean Fever / immunology. Female. Granulocytes / immunology. Humans. Infant. Infection / blood. Infection / diagnosis. Infection / immunology. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / immunology. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. S100A12 Protein. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Arthritis, Juvenile.
  • MedlinePlus Health Information. consumer health - Juvenile Arthritis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2001 May;107(9):1127-35 [11342576.001]
  • [Cites] J Exp Med. 2007 Sep 3;204(9):2131-44 [17724127.001]
  • [Cites] J Clin Invest. 2001 Oct;108(7):949-55 [11581294.001]
  • [Cites] N Engl J Med. 2001 Dec 13;345(24):1748-57 [11742050.001]
  • [Cites] Arthritis Rheum. 2002 Aug15;47(4):429-33 [12209491.001]
  • [Cites] Lancet. 2003 Apr 12;361(9365):1270-2 [12699958.001]
  • [Cites] Gut. 2003 Jun;52(6):847-53 [12740341.001]
  • [Cites] Rheumatology (Oxford). 2003 Nov;42(11):1383-9 [12832707.001]
  • [Cites] J Rheumatol. 2004 Feb;31(2):390-2 [14760812.001]
  • [Cites] Arthritis Rheum. 2004 Apr;50(4):1286-95 [15077313.001]
  • [Cites] J Pathol. 2004 Nov;204(3):311-6 [15476267.001]
  • [Cites] Curr Clin Top Infect Dis. 1991;11:35-51 [1651090.001]
  • [Cites] Arthritis Rheum. 1997 Jul;40(7):1202-9 [9214419.001]
  • [Cites] Lancet. 1997 Aug 23;350(9077):575-80 [9284789.001]
  • [Cites] Ann Rheum Dis. 1998 Jan;57(1):38-41 [9536821.001]
  • [Cites] Br J Rheumatol. 1998 May;37(5):562-9 [9651086.001]
  • [Cites] Clin Rheumatol. 1998;17(3):258-60 [9694067.001]
  • [Cites] Lancet. 1998 Mar 28;351(9107):969-73 [9734957.001]
  • [Cites] Curr Opin Rheumatol. 1998 Sep;10(5):459-67 [9746862.001]
  • [Cites] Baillieres Clin Rheumatol. 1998 May;12(2):245-71 [9890097.001]
  • [Cites] Cell. 1999 Jun 25;97(7):889-901 [10399917.001]
  • [Cites] J Biol Chem. 1999 Sep 3;274(36):25291-6 [10464253.001]
  • [Cites] Medicine (Baltimore). 1961 Feb;40:1-30 [13734791.001]
  • [Cites] Arthritis Rheum. 2004 Dec;50(12):3762-71 [15593206.001]
  • [Cites] J Exp Med. 2005 May 2;201(9):1479-86 [15851489.001]
  • [Cites] J Exp Med. 2005 May 2;201(9):1355-9 [15867089.001]
  • [Cites] Arthritis Rheum. 2005 Jun;52(6):1794-803 [15934079.001]
  • [Cites] Nucl Med Commun. 2006 Mar;27(3):205-11 [16479239.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):581-92 [16899778.001]
  • [Cites] Nat Clin Pract Rheumatol. 2006 Jan;2(1):28-34 [16932649.001]
  • [Cites] Ann Rheum Dis. 2006 Nov;65(11):1427-32 [16707534.001]
  • [Cites] J Biol Chem. 2007 Feb 9;282(6):4218-31 [17158877.001]
  • [Cites] Crit Care Med. 2007 May;35(5):1369-75 [17414728.001]
  • [Cites] Arthritis Rheum. 2007 Jun;56(6):1954-65 [17530721.001]
  • [Cites] Gut. 2007 Dec;56(12):1706-13 [17675327.001]
  • [Cites] Ann Rheum Dis. 2008 Mar;67(3):302-8 [17947302.001]
  • [Cites] Nat Clin Pract Rheumatol. 2007 Jul;3(7):382-90 [17599072.001]
  • [Cites] Ann Rheum Dis. 2007 Aug;66(8):1020-5 [17223658.001]
  • [Cites] J Leukoc Biol. 2001 Jun;69(6):986-94 [11404386.001]
  • (PMID = 19035478.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 AR041138-05
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / S100 Proteins; 0 / S100A12 Protein; 0 / S100A12 protein, human
  • [Other-IDs] NLM/ NIHMS58669; NLM/ PMC2680303
  •  go-up   go-down


79. Cruse JM, Lewis RE, Pierce S, Lam J, Tadros Y: Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias. Exp Mol Pathol; 2005 Aug;79(1):39-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias.
  • CD7 and CD56 expression at diagnosis has been associated with low remission rates and biological aggressiveness in a significant proportion of acute leukemias.
  • Among 46 patients with acute myeloid leukemia, we found CD7 expression in 15 cases (32.6%) and CD56 positivity in 10 patients (21.7%).
  • Six of these myeloid leukemia cases (13%) showed expression of both CD7 and CD56.
  • Among the 10 that were acute myeloblastic leukemia, 8 expressed CD7, 4 expressed CD56, and 4 were positive for CD79a.
  • Thus, these markers were expressed early in hemopoietic ontogeny in the lesser-differentiated acute myeloid leukemia subtypes, including FAB M0, M1, and M2.
  • Whereas CD7 and CD56 were each positive in 4 cases of acute myelomonocytic leukemia (FAB M4 subtype), there was no CD79a expression in the M4 cases.
  • CD7 is expressed by mature T cells, NK cells, and an immature myeloid cell subset.
  • By contrast, CD79a is a B cell marker that is assigned a high score of 2.0 in the differentiation of acute leukemias of ambiguous lineage in the WHO classification.
  • The aberrant expression of CD7, CD56, and CD79a, representing the capacity of these leukemias for trilineal expression of leukocyte differentiation antigens, portends a poor prognosis.
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, CD56 / biosynthesis. Antigens, CD7 / biosynthesis. Biomarkers, Tumor / analysis. Leukemia, Myeloid, Acute / metabolism. Receptors, Antigen, B-Cell / biosynthesis

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16005710.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD56; 0 / Antigens, CD7; 0 / Antigens, CD79; 0 / Biomarkers, Tumor; 0 / CD79A protein, human; 0 / Receptors, Antigen, B-Cell
  •  go-up   go-down


80. Pinto AC, Silva LF, Cavalcanti BC, Melo MR, Chaves FC, Lotufo LV, de Moraes MO, de Andrade-Neto VF, Tadei WP, Pessoa CO, Vieira PP, Pohlit AM: New antimalarial and cytotoxic 4-nerolidylcatechol derivatives. Eur J Med Chem; 2009 Jun;44(6):2731-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mono-O-methyl ethers 6 and 7 inhibited the in vitro growth of human tumor cell lines HCT-8 (colon carcinoma), SF-295 (central nervous system), LH-60 (human myeloblastic leukemia) and MDA/MB-435 (melanoma).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19084293.001).
  • [ISSN] 1768-3254
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / 4-nerolidylcatechol; 0 / Antimalarials; 0 / Antineoplastic Agents, Phytogenic; 0 / Catechols; 0 / Plant Extracts
  •  go-up   go-down


81. Tosić N, Stojiljković M, Colović N, Colović M, Pavlović S: Acute myeloid leukemia with NUP98-HOXC13 fusion and FLT3 internal tandem duplication mutation: case report and literature review. Cancer Genet Cytogenet; 2009 Sep;193(2):98-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia with NUP98-HOXC13 fusion and FLT3 internal tandem duplication mutation: case report and literature review.
  • We report a case of de novo AML M4 subtype, with a t(11;12)(p15;q13) translocation, generating a NUP98-HOXC13 chimeric transcript.
  • The patient was also positive for FLT3 internal tandem duplication (ITD), another molecular marker for the disease.
  • Comparative study of data on the fusion of HOXC cluster and NUP98 gene revealed that it is a rare event, found exclusively in AML patients.
  • To our knowledge, this is the first case of t(11;12)(p15;q13) in de novo AML-M4 in association with FLT3 ITD mutation.
  • [MeSH-major] Gene Duplication. Homeodomain Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Mutation. Nuclear Pore Complex Proteins / genetics. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19665070.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HOXC13 protein, human; 0 / Homeodomain Proteins; 0 / Nuclear Pore Complex Proteins; 0 / Nup98 protein, human; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Number-of-references] 32
  •  go-up   go-down


82. Turhan N, Yürür-Kutlay N, Topcuoglu P, Sayki M, Yüksel M, Gürman G, Tükün A: Translocation (13;17)(q14;q25) as a novel chromosomal abnormality in acute myeloid leukemia-M4. Leuk Res; 2006 Jul;30(7):903-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation (13;17)(q14;q25) as a novel chromosomal abnormality in acute myeloid leukemia-M4.
  • We report a case of AML-M4 in which G-band karyotyping revealed a previously unreported t(13;17)(q14;q25) in metaphase preparations.
  • This report of AML-M4 harboring t(13;17)(q14;q25) as a unique cytogenetic abnormality provides more data on the leukomogenesis with rearrangements related with 13q14 and 17q25.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 13 / genetics. Chromosomes, Human, Pair 17 / genetics. Leukemia, Myelomonocytic, Acute / genetics. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16469377.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


83. Zhang L, Alsabeh R, Mecucci C, La Starza R, Gorello P, Lee S, Lill M, Schreck R: Rare t(1;11)(q23;p15) in therapy-related myelodysplastic syndrome evolving into acute myelomonocytic leukemia: a case report and review of the literature. Cancer Genet Cytogenet; 2007 Oct 1;178(1):42-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare t(1;11)(q23;p15) in therapy-related myelodysplastic syndrome evolving into acute myelomonocytic leukemia: a case report and review of the literature.
  • Balanced chromosome rearrangements are the hallmark of therapy-related leukemia that develops in patients treated with topoisomerase II inhibitors.
  • With time, the patient's disorder progressed to acute myelomonocytic leukemia with cytogenetic evidence of clonal evolution.
  • To our knowledge, this is the first report of a patient presenting with a myelodysplastic syndrome with isolated t(1;11) (q23;p15), which evolved into therapy-related acute myeloid leukemia (t-AML).
  • This patient is the third reported with this cytogenetic rearrangement and t-AML, and is compared with the other two reports of t(1;11)(q23;p15).
  • [MeSH-major] Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 11. Leukemia, Myelomonocytic, Acute / genetics. Myelodysplastic Syndromes / genetics. Myelodysplastic Syndromes / pathology. Myelodysplastic Syndromes / therapy. Translocation, Genetic
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Neutrophils / metabolism


84. Hubeek I, Peters GJ, Broekhuizen R, Zwaan CM, Kaaijk P, van Wering ES, Gibson BE, Creutzig U, Janka-Schaub GE, den Boer ML, Pieters R, Kaspers GJ: In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia. Haematologica; 2006 Jan;91(1):17-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia.
  • BACKGROUND AND OBJECTIVES: Cytarabine (ara-C) is a key drug in the treatment of acute leukemia.
  • DESIGN AND METHODS: Using the MTT assay, we determined in vitro sensitivity and cross-resistance to deoxynucleoside analogs in 362 acute leukemia samples from untreated children and 32 normal bone marrow mononuclear cell samples.
  • RESULTS: Normal bone marrow samples were significantly more resistant to ara-C, cladribine and fludarabine than were acute myeloid leukemia (AML) samples and significantly more resistant to ara-C and fludarabine than were acute lymphoblastic leukemia (ALL) samples.
  • The only drug to which AML samples were more sensitive in vitro than ALL was cladribine.
  • AML FAB M5 was significantly more sensitive in vitro to ara-C and cladribine than FAB M1/2 or FAB M4.
  • A paired analysis of 60 AML and 99 ALL samples demonstrated significant cross-resistance between all four deoxynucleoside analogs.
  • Cross-resistance was also observed between ara-C and etoposide (Rp=0.54, p<0.0001), and ara-C and daunorubicin (Rp=0.48, p<0.0001) in AML.
  • INTERPRETATION AND CONCLUSIONS: Cladribine appears to be a useful drug in AML, particularly in FAB M5.
  • We observed cross-resistance between ara-C and other deoxynucleoside analogs, as well as between ara-C and drugs with different modes of action in childhood acute leukemia.
  • [MeSH-major] Drug Resistance, Multiple. Leukemia / drug therapy. Nucleosides / therapeutic use
  • [MeSH-minor] Acute Disease. Child. Cytarabine / therapeutic use. Drug Screening Assays, Antitumor. Humans

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434366.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Nucleosides; 04079A1RDZ / Cytarabine
  •  go-up   go-down


85. Liu M, Wei XD, Lü XD, Fan RH, Yin QS, Zhou J: [Expression of NF-kappaB mRNA in acute myeloid leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr;18(2):359-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of NF-kappaB mRNA in acute myeloid leukemia].
  • This study was aimed to investigate the expression level of NF-kappaB mRNA in acute myeloid leukemia (AML) using real time fluorescence quantitative polymerase chain reduction (qPCR) detection and to explore the effect of NF-kappaB mRNA in pathogenesis of AML.
  • The fresh bone marrow was collected from 60 newly diagnosed patients with AML, the total RNA was extracted by means of RTIzoL, the cDNA was synthesized, the expression of NF-kappaB mRNA was detected by qPCR using GAPDH as internal reference.
  • The results showed that the expression of NF-kappaB mRNA in patients with AML was higher than that in normal healthy persons with significant difference (p<0.05), the expression of NF-kappaB mRNA in patients with AML-M4 and -M5 were higher than that in patients with AML-M1, -M2 and -M3.
  • It is concluded that the expression of NF-kappaB mRNA is higher in patients with AML.
  • The up-regulation of NF-kappaB expression in patients with AML may play an important role in pathogenesis of AML.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20416168.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / RNA, Messenger
  •  go-up   go-down


86. Liu LB, Li WM, Zou P, He W, Zhang M: [Depressing the immune escape of acute myelomonocytic leukemia via an anti-Fas ribozyme]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct;14(5):862-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Depressing the immune escape of acute myelomonocytic leukemia via an anti-Fas ribozyme].
  • In order to investigate the inhibition role of anti-Fas hammerhead ribozyme on Fas expression and Fas-mediated apoptosis in CTLL-2 cells (mouse CTL cell line), and to explore a new way for enhancing the ability of T cells against Leukemia in donor lymphocytes infusion, CTLL-2 cells were transfected with pEGFP-RZ596 and pEGFPC1 (mock-transfected) via electroporation.
  • The killing effect of CTL against WEHI-3 (mouse acute myelomonocytic leukemia cell line) highly expressing FasL in vitro was detected by MTT assay.
  • It is concluded that anti-Fas ribozyme can remarkably decrease Fas expression on CTLL-2 cells, so as to avoid Fas-mediated apoptosis by Fas ligand on WEHI-3 cells, and to enhance their killing activity against WEHI-3 cells, as a result, the immune escape of acute myelomonocytic leukemia was depressed.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096877.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Fas Ligand Protein; 0 / RNA, Catalytic; 0 / hammerhead ribozyme
  •  go-up   go-down


87. Potenza L, Luppi M, Riva G, Morselli M, Ferrari A, Imovilli A, Giacobbi F, Temperani P, Donelli A, Narni F, Torelli G: Isolated extramedullary relapse after autologous bone marrow transplantation for acute myeloid leukemia: case report and review of the literature. Am J Hematol; 2006 Jan;81(1):45-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated extramedullary relapse after autologous bone marrow transplantation for acute myeloid leukemia: case report and review of the literature.
  • Isolated extramedullary relapse (IEMR) is a pattern of acute myeloid leukemia (AML) relapse post-allogeneic bone marrow transplantation (alloBMT).
  • We report a case of a woman with M4 AML who experienced IEMR post-autoBMT and review the related literature.
  • The review suggests that an M2 or M4 French-American-British (FAB) phenotype, intermediate cytogenetic risk group, and chromosome 8 abnormalities are more frequently associated with the occurrence of IEMR.
  • [MeSH-major] Bone Marrow Transplantation. Leukemia, Myeloid, Acute / therapy


88. Chang ST, Hsieh YC, Lee LP, Tzeng CC, Chuang SS: Acute myelomonocytic leukemia with abnormal eosinophils: a case report with multi-modality diagnostic work-up. Chang Gung Med J; 2006 Sep-Oct;29(5):532-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelomonocytic leukemia with abnormal eosinophils: a case report with multi-modality diagnostic work-up.
  • Acute myeloid leukemia (AML) with recurrent genetic abnormalities often carries a favorable prognosis.
  • AML with inv(16)(p13q22) occurs predominantly in younger patients and usually shows granulocytic and monocytic differentiation with abnormal eosinophils.
  • It is referred to as acute myelomonocytic leukemia with abnormal eosinophils (AMML Eo).
  • This case illustrates a typical AMML Eo confirmed by a multi-modality diagnostic approach including morphology, cytochemistry, flow cytometry, immunohistochemistry, and conventional cytogenetic study.
  • [MeSH-major] Eosinophils / pathology. Leukemia, Myelomonocytic, Acute / diagnosis

  • Genetic Alliance. consumer health - Acute Myelomonocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214400.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


89. Abe A, Kiyoi H, Ninomiya M, Yamazaki T, Murase T, Ozeki K, Suzuki M, Hayakawa F, Katsumi A, Emi N, Naoe T: Establishment of a stroma-dependent human acute myelomonocytic leukemia cell line, NAMO-2, with FLT3 tandem duplication. Int J Hematol; 2006 Nov;84(4):328-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of a stroma-dependent human acute myelomonocytic leukemia cell line, NAMO-2, with FLT3 tandem duplication.
  • We have established a stroma-dependent myelomonocytic cell line, NAMO-2, with FLT3 internal tandem duplication (FLT3/ITD).
  • Leukemia cells from a patient with acute myelomonocytic leukemia were administered to form subcutaneous tumors in nude mice, which were maintained successively, although we failed to establish continuously growing cells from the original leukemia cell culture.
  • The leukemia cells showed continuous growth dependent on this stroma, and this cell line was named NAMO-2.
  • NAMO-2 provides a useful tool to analyze adherence-dependent survival signaling of leukemia with FLT3/ITD and a model for the screening of FLT3 kinase inhibitors.
  • [MeSH-major] Cell Line, Tumor. Leukemia, Myelomonocytic, Acute / pathology. Stromal Cells / physiology. Tandem Repeat Sequences. fms-Like Tyrosine Kinase 3 / genetics


90. Dunphy CH, Tang W: The value of CD64 expression in distinguishing acute myeloid leukemia with monocytic differentiation from other subtypes of acute myeloid leukemia: a flow cytometric analysis of 64 cases. Arch Pathol Lab Med; 2007 May;131(5):748-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of CD64 expression in distinguishing acute myeloid leukemia with monocytic differentiation from other subtypes of acute myeloid leukemia: a flow cytometric analysis of 64 cases.
  • CONTEXT: Flow cytometric immunophenotyping is a useful ancillary tool in the diagnosis and subclassification of acute myeloid leukemias (AMLs).
  • A recent study concluded that CD64 is sensitive and specific for distinguishing AMLs with a monocytic component (ie, AML M4 and AML M5) from other AML subtypes.
  • However, in that study, the intensity of CD64 was not well defined and the number of non-M4/non-M5 AMLs was small.
  • OBJECTIVE: To evaluate the usefulness of CD64 by flow cytometric immunophenotyping in distinguishing AMLs with monocytic differentiation from other AML subtypes.
  • RESULTS: CD64 was expressed in AML subtypes M0 to M5 in varying intensities: heterogeneously expressed in 1 of 7 M0s; dimly expressed in 3 of 11 M1s; dimly and moderately expressed in 6 and 2 of 17 M2s, respectively; dimly and moderately expressed in 5 and 1 of 7 M3s, respectively; dimly expressed in 4 of 9 M4s; and heterogeneously, moderately, and strongly expressed in 1, 3, and 3 of 7 M5s, respectively.
  • CONCLUSIONS: Strong CD64 expression distinguishes AML M5; however, heterogeneous, dim, or moderate expression in itself does not distinguish M0 through M4 subtypes from M5 with dim to moderate CD64 expression.
  • However, any CD64 expression associated with strong CD15 expression distinguishes AML M4 or M5, from other AML subtypes.
  • [MeSH-major] Biomarkers, Tumor / analysis. Leukemia, Myeloid / diagnosis. Receptors, IgG / biosynthesis
  • [MeSH-minor] Acute Disease. Antigens, CD / analysis. Flow Cytometry. HLA-DR Antigens. Humans. Immunophenotyping. Monocytes / metabolism

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488160.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / HLA-DR Antigens; 0 / Receptors, IgG
  •  go-up   go-down


91. Liu Y, Chao X, Gu W, Hua X, Xu N: Acute thrombosis in superior mesenteric artery as first symptom in a AML patient. Int J Gen Med; 2008;1:7-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute thrombosis in superior mesenteric artery as first symptom in a AML patient.
  • It is well known that acute leukemia may accompany thromboembolic events; even severe thrombocytopenia does not prevent thrombosis.
  • Most thromboembolism is localized in venous vessels in acute leukemic patients and it happens rarely in the artery.
  • We report a case of acute thrombosis in the superior mesenteric artery as the first symptom in a patient suffering from acute myeloid leukemia (FAB M4).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2007 Sep;132(3):936-45 [17573514.001]
  • [Cites] Br J Haematol. 2007 Aug;138(4):430-45 [17608766.001]
  • [Cites] Acta Haematol. 2001;106(1-2):25-32 [11549774.001]
  • [Cites] Semin Thromb Hemost. 2005 Feb;31(1):104-10 [15706482.001]
  • [Cites] J Thromb Haemost. 2005 Sep;3(9):1985-92 [16102104.001]
  • [Cites] Am J Hematol. 2006 Mar;81(3):171-4 [16493609.001]
  • [Cites] Pediatr Hematol Oncol. 2006 Apr-May;23(3):207-16 [16517537.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2216-22 [16804111.001]
  • [Cites] Leukemia. 2007 Jan;21(1):79-83 [16932337.001]
  • [Cites] Semin Thromb Hemost. 2007 Jun;33(4):435-48 [17525901.001]
  • [Cites] Semin Thromb Hemost. 2007 Jun;33(4):303-12 [17525887.001]
  • (PMID = 20428399.001).
  • [ISSN] 1178-7074
  • [Journal-full-title] International journal of general medicine
  • [ISO-abbreviation] Int J Gen Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2840534
  • [Keywords] NOTNLM ; acute leukemia / pathogenesis / thromboembolism
  •  go-up   go-down


92. Yamamoto Y, Uchima T, Konoike Y, Nakamine H: Myeloid sarcoma in the nasal cavities that developed during the course of acute myelomonocytic leukemia. J Clin Exp Hematop; 2010;50(2):167-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid sarcoma in the nasal cavities that developed during the course of acute myelomonocytic leukemia.
  • [MeSH-major] Leukemia, Myelomonocytic, Acute / pathology. Nasal Cavity / pathology. Neoplasms, Multiple Primary / pathology. Nose Neoplasms / pathology. Sarcoma, Myeloid / pathology


93. Haase R, Merkel N, Diwan O, Elsner K, Kramm CM: Leukapheresis and exchange transfusion in children with acute leukemia and hyperleukocytosis. A single center experience. Klin Padiatr; 2009 Nov-Dec;221(6):374-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukapheresis and exchange transfusion in children with acute leukemia and hyperleukocytosis. A single center experience.
  • BACKGROUND: The risk of severe complications or death during the initial period of acute leukemia was markedly decreased due to the progress in pediatric oncology and use of simple measures like hyperhydration, forced diuresis, treatment of hyperuricemia, correction of electrolyte and coagulation disturbances and the careful use of antileukemic drugs.
  • The incidence of leukostasis and tumor lysis syndrome depends on absolute initial white blood cell counts and the underlying type of leukemia.
  • METHODS: Records of all pediatric patients who were newly diagnosed with acute leukemia between 1 / 1998 und 12 / 2008 were retrospectively reviewed for presence of hyperleukocytosis(white blood cell count > 100 GPT / l) at diagnosis and subsequent leukapheresis or exchange transfusion in regards to the clinical outcome.
  • RESULTS: At diagnosis 11 (14 % ) of 77 children with acute leukemia (7 acute lymphoblastic leukemia / ALL; 4 acute myeloblastic leukemia /AML) had hyperleukocytosis.
  • 4 patients (2 ALL, 2 AML) received exchange transfusion and 2 others (1 ALL, 1 AML) underwent leukapheresis.
  • The exact impact of leukapheresis or exchange transfusion on short and long term outcome in pediatric patients with acute leukemia and initial hyperleukocytosis has to be evaluated in future multicentre studies or by the formation of clinical registries.
  • [MeSH-major] Exchange Transfusion, Whole Blood. Leukapheresis. Leukemia, Myeloid, Acute / therapy. Leukocytosis / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Infant. Leukocyte Count. Male. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart.New York.
  • (PMID = 19890790.001).
  • [ISSN] 1439-3824
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


94. Bekou V, Franke I, Gollnick H, Leverkus M: [Livid polycyclic plaques of the lower extremities]. Hautarzt; 2008 Nov;59(11):942-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 10%-55% of patients, leukemia cutis (LC) manifest as a symptom of acute myelomonocytic leukemia and is associated with a poor overall prognosis.
  • Disseminated bluish-violet or red-brownish papules and plaques, nodules and also hemorrhagic ulcers may dominate the initial clinical picture.
  • The role of the dermatologist is the rapid clinical and dermatohistopathological diagnosis in order to allow immediate, adequate treatment of the patient's underlying systemic disease.
  • [MeSH-major] Leg Dermatoses / pathology. Leukemia, Myelomonocytic, Acute / pathology. Lower Extremity / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Dermatol. 2006 Mar;31(2):218-21 [16487095.001]
  • [Cites] Nat Biotechnol. 2006 Oct;24(10):1270-8 [17013374.001]
  • [Cites] J Cutan Pathol. 2008 Feb;35(2):180-5 [18190442.001]
  • [Cites] Leuk Lymphoma. 2002 Mar;43(3):565-74 [12002760.001]
  • [Cites] Am J Clin Pathol. 1997 Jun;107(6):637-42 [9169659.001]
  • [Cites] Am J Dermatopathol. 2007 Aug;29(4):334-41 [17667165.001]
  • [Cites] Br J Dermatol. 2000 Oct;143(4):773-9 [11069455.001]
  • [Cites] Am J Clin Pathol. 2008 Jan;129(1):130-42 [18089498.001]
  • (PMID = 18712322.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


95. Bonci D, Musumeci M, Coppola V, Addario A, Conticello C, Hahne M, Gulisano M, Grignani F, De Maria R: Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity. Haematologica; 2008 Dec;93(12):1899-902
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity.
  • Resistance to chemotherapy-induced cell death represents a major obstacle in the treatment of acute myeloid leukemia.
  • We investigated APRIL expression and activity in acute myeloid leukemia.
  • We found that APRIL mRNA and protein, including the secreted form, are expressed in leukemic cells of patients with M0, M2 and M4 acute myeloid leukemia subtypes but not in normal hematopoietic progenitors.
  • Conversely, blocking APRIL function by recombinant soluble APRIL receptors increased chemotherapeutic drugs-induced cell adeath in acute myeloid leukemia cells.
  • These results indicate that APRIL acts in an autocrine fashion to protect acute myeloid leukemia cells from drug-induced death and foresee a therapeutic potential of APRIL antagonists in the treatment of acute myeloid leukemia.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Drug Resistance, Neoplasm. Leukemia, Myeloid, Acute / pathology. Tumor Necrosis Factor Ligand Superfamily Member 13 / antagonists & inhibitors

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838478.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tumor Necrosis Factor Ligand Superfamily Member 13
  •  go-up   go-down


96. Kar R, Rao S, Pati HP: Systemic mastocytosis with acute myelomonocytic leukemia: a case report. Indian J Hematol Blood Transfus; 2008 Dec;24(4):182-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic mastocytosis with acute myelomonocytic leukemia: a case report.
  • Bone marrow mastocytosis may be associated with many clonal non mast cell hematological neoplasms and its association with acute myeloid leukemia especially with t (8;.
  • We describe an interesting case of coexistence of systemic mastocytosis with acute myelomonocytic leukemia in a young child.
  • Diagnosis of acute myelomonocytic leukemia was based on bone marrow aspirate findings coupled with cytochemistry.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hematol. 2000 Dec;65(4):307-9 [11074560.001]
  • [Cites] Br J Haematol. 2000 Dec;111(4):991 [11167732.001]
  • [Cites] N Engl J Med. 2003 Mar 27;348(13):1201-14 [12660384.001]
  • [Cites] Am J Hematol. 2003 May;73(1):12-7 [12701114.001]
  • [Cites] J Clin Pathol. 2004 Mar;57(3):324-8 [14990611.001]
  • [Cites] Leuk Res. 2007 Feb;31(2):261-5 [16876862.001]
  • [Cites] Indian J Pathol Microbiol. 2007 Jul;50(3):655-8 [17883174.001]
  • [Cites] Haematologica. 2008 Jan;93(1):49-56 [18166785.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1429-39 [16948123.001]
  • [Cites] J Clin Pathol. 2004 Jun;57(6):604-8 [15166264.001]
  • [Cites] J Allergy Clin Immunol. 2004 Jul;114(1):28-33 [15241340.001]
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):35-48 [15621779.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6787-92 [16203765.001]
  • (PMID = 23100960.001).
  • [ISSN] 0971-4502
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3475428
  • [Keywords] NOTNLM ; Acute myeloid leukemia / Systemic mastocytosis / Toluidine blue
  •  go-up   go-down


97. Kaufman DW, Anderson TE, Issaragrisil S: Risk factors for leukemia in Thailand. Ann Hematol; 2009 Nov;88(11):1079-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for leukemia in Thailand.
  • A case-control study of adult-onset leukemia was conducted in Bangkok, Thailand to explore the contribution of cellular telephone use and other factors to the etiology of the disease; 180 cases (87 acute myeloblastic leukemia, 40 acute lymphoblastic leukemia, 44 chronic myelogenous leukemia, eight chronic lymphocytic leukemia, one unclassified acute leukemia) were compared with 756 age- and sex-matched hospital controls.
  • Myeloid leukemia (acute and chronic combined) was associated with benzene (OR, 3.9; 95% confidence interval, 1.3-11), a nonspecific group of other solvents (2.3; 1.1-4.9), occupational pesticides that were mostly unspecified (3.8; 2.1-7.1), and working with or near powerlines (4.3; 1.3-15).
  • [MeSH-major] Leukemia / epidemiology
  • [MeSH-minor] Adult. Aged. Benzene / adverse effects. Case-Control Studies. Cell Phones. Electromagnetic Fields / adverse effects. Female. Humans. Leukemia, Radiation-Induced / epidemiology. Leukemia, Radiation-Induced / etiology. Male. Middle Aged. Occupational Exposure. Pesticides / adverse effects. Radiography / adverse effects. Risk Factors. Smoking / epidemiology. Solvents / adverse effects. Thailand / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BENZENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19294385.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Pesticides; 0 / Solvents; J64922108F / Benzene
  •  go-up   go-down


98. Chen YX, Zhang MY, Xiong S, Qian CW, Wang YF: [Analysis of the relationship between nm23-H1 gene and human chronic myeloblastic leukemia using siRNA]. Sheng Wu Gong Cheng Xue Bao; 2006 May;22(3):403-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of the relationship between nm23-H1 gene and human chronic myeloblastic leukemia using siRNA].
  • To investigate the relationship between nm23-H1 gene and human chronic myeloblastic leukemia we designed siRNAs which target nm23-H1 gene.
  • Therefore nm23-H1 gene might be a potential target of leukemia treatment.
  • [MeSH-major] Leukemia, Erythroblastic, Acute / genetics. Leukemia, Erythroblastic, Acute / pathology. NM23 Nucleoside Diphosphate Kinases / genetics. RNA, Small Interfering / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755918.001).
  • [ISSN] 1000-3061
  • [Journal-full-title] Sheng wu gong cheng xue bao = Chinese journal of biotechnology
  • [ISO-abbreviation] Sheng Wu Gong Cheng Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NM23 Nucleoside Diphosphate Kinases; 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 2.7.4.6 / NME1 protein, human
  •  go-up   go-down


99. Lu G, Yin CC, Medeiros LJ, Abruzzo LV: Deletion 15q as the sole abnormality in acute myeloid leukemia: report of three cases and review of the literature. Cancer Genet Cytogenet; 2009 Jan 15;188(2):118-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion 15q as the sole abnormality in acute myeloid leukemia: report of three cases and review of the literature.
  • Deletions within the long arm of chromosome 15, a recurrent abnormality in myeloid malignancies, have been reported previously as a sole abnormality in only eight cases of acute myeloid leukemia (AML).
  • We describe three new cases of AML with this abnormality, all adult women (age, 41-66 years).
  • Two cases were acute myelomonocytic leukemia (FAB AML-M4), and one was acute myeloblastic leukemia with maturation (FAB AML-M2).
  • The deletion was identified at initial diagnosis in one patient and at relapse in the other two.
  • Taken together with the eight previously reported cases, we conclude that deletions in chromosome 15 are associated with AML, both in cases that arise de novo or in the setting of a myeloproliferative disorder or myelodysplastic syndrome.
  • These cases often show features of myelomonocytic or monocytic differentiation.
  • The prognosis is poor, with survival similar to other AML cases with unfavorable cytogenetic changes.
  • [MeSH-major] Chromosomes, Human, Pair 15. Leukemia, Myeloid, Acute / genetics. Sequence Deletion

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19100517.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


100. Kufner S, Fleischer RP, Kroell T, Schmid C, Zitzelsberger H, Salih H, de Valle F, Treder W, Schmetzer HM: Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. Cancer Immunol Immunother; 2005 Oct;54(10):953-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes.
  • Functional dendritic cells (DC) are professional antigen presenting cells (APC) and can be generated in vitro from leukemic cells from acute myeloid leukemia AML patients, giving rise to APC of leukemic origin presenting leukemic antigens (DC(leu)).
  • We have already shown that DC can be successfully generated from AML and myeloplastic syndromes (MDS) cells in serum-free 'standard' medium (X-vivo + GM-CSF + IL-4 +TNFalpha + FL) in 10-14 days.
  • In this study, we present that DC counts generated from mononuclear cells (MNC) varied between 20% (from 55 MDS samples), 34% (from 100 AML samples) and 25% (from 38 healthy MNC samples) medium.
  • DC harvests were highest in monocytoid FAB types (AML-M4/M5, MDS-CMML) and independent from cytogenetic risk groups, demonstrating that DC-based strategies can be applied for patients with all cytogenetic risk groups.
  • Proof of the clonal derivation of DC generated was obtained in five AML and four MDS cases with a combined FISH/immunophenotype analysis (FISH-IPA): The clonal numerical chromosome aberrations of the diseases were regularly codetectable with DC markers; however, not with all clonal cells being convertible to leukemia-derived DC(leu) (on average, 53% of blasts in AML or MDS).
  • In 41 AML and 13 MDS cases with a suitable antigen expression, we could confirm FISH-IPA data by Flow cytometry: although DC(leu) are regularly detectable, on average only 57% of blasts in AML and 64% of blasts in MDS were converted to DC(leu).
  • After coculture with DC in mixed lymphocyte reactions (MLR), autologous T cells from AML and MDS patients proliferate and upregulate costimulatory receptors.
  • The specific lysis of leukemic cells by autologous T cells could be demonstrated in three cases with AML in a Fluorolysis assay.
  • (1) the generation of DC is regularly possible in AML and also in MDS under serum-free conditions. (2) Clonal/leukemia-derived DC(leu) can be regularly generated from MDS and AML-MNC; however, not with all blasts being converted to DC(leu) and not all DC generated carrying leukemic markers.
  • We recommend to select DC(leu) for vaccinations or ex vivo T-cell activations to avoid contaminations with non-converted blasts and non-leukemia-derived DC and to improve the harvest of specific, anti-leukemic T cells.
  • DC and DC-primed T cells could provide a practical strategy for the immunotherapy of AML and MDS.
  • [MeSH-major] Dendritic Cells / immunology. Leukemia, Myeloid / immunology. Leukocytes, Mononuclear / immunology. Myelodysplastic Syndromes / immunology
  • [MeSH-minor] Acute Disease. Adult. Aged. Antigen-Presenting Cells. Antigens, CD. Antigens, CD80 / immunology. Antigens, CD80 / metabolism. Blast Crisis. Cell Culture Techniques. Culture Media, Serum-Free. Female. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Humans. Immunoglobulins / immunology. Immunoglobulins / metabolism. Interleukin-4 / pharmacology. Lymphocyte Activation. Male. Membrane Glycoproteins / immunology. Membrane Glycoproteins / metabolism. Middle Aged. T-Lymphocytes / immunology. T-Lymphocytes, Cytotoxic. Tumor Necrosis Factor-alpha / pharmacology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15789235.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD80; 0 / CD83 antigen; 0 / Culture Media, Serum-Free; 0 / Immunoglobulins; 0 / Membrane Glycoproteins; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down






Advertisement